Version 2.2
Institutional Outcomes Report
2012Q2
Sample Hospital
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
If User desires to publish or otherwise distribute or use, in whole or in part, any aggregate data or reports provided by
ACCF, or produced in connection with or derived from NCDR, with the exception of strictly internal use within User's
organization, User must first obtain the prior express written consent of ACCF. To the extent User is permitted to publish
aggregate data, such aggregate data and any related information published in connection with it must be reviewed and
approved by ACCF prior to publication.
National Cardiovascular Data Registry
®
ACTION Registry -GWTG™
800-257-4737
www.ncdr.com •[email protected]
©2011 American College of Cardiology Foundation
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
1
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Table of Contents
Inclusion Summary
3
Quarters included in this report:
3
Comparison group included in this report:
3
Release Notes:
3
Frequently used terminology:
4
Executive Summary
7
Section IA: Composite Measures
7
Section IIA: AMI Performance Measures
10
Section III: Quality Metrics
14
Section IV: Participant Graphs
16
Detail Section Line Reference
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
21
Rev: 5
2
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Inclusion Summary
Quarters included in this report:
Timeframe
Benchmark Inclusion Status
Submission Type
All Patients
STEMI
NSTEMI
2011Q3
Limited
32
9
23
Yes
2011Q4
Limited
53
11
42
Yes
2012Q1
Limited
63
26
37
Yes
2012Q2
Limited
59
30
29
Yes
Included in Executive Summary
Comparison group included in this report:
Comparison
Group
Comparison Group Name
Number of US Hospitals
per Comparison Group
2
No Cath Lab Services on-site, or only Diagnostic
Catheterizations
18
3
Diagnostic Caths and PCIs performed on-site
111
4
Cardiac Surgery, to include Diagnostic Caths and
PCIs, are performed on-site (Region 1)
36
5
Cardiac Surgery, to include Diagnostic Caths and
PCIs, are performed on-site (Region 2)
213
6
Cardiac Surgery, to include Diagnostic Caths and
PCIs, are performed on-site (Region 3)
148
7
Cardiac Surgery, to include Diagnostic Caths and
PCIs, are performed on-site (Region 4)
59
Your Hospital's
Comparison Group
X
Release Notes:
ACTION Registry®-GWTG Outcomes Report Release Notes for 2012 Q2
Report Changes:
1. Quality Metric 24, Detail Line 1027 - The earliest date for all anticoagulants will be checked. Previously if UFH was outside of the first 24 hours it would exclude
the record even if another anticoagulant was within the 24 hours.
2. Quality Metric 31, Detail Line 1034 - The algorithm was changed to exclude patients with an LDL "Value Out of Range" selected.
3. Quality Metric 25, Detail Lines 1028, 1197, 1568, and 1925 - The algorithm was changed to not evaluate Primary PCI for NSTEMI records.
4. Detail Lines 1375, 1741, 2056 - An additional line was added to include the proportion of non-CABG related transfusions.
5. Detail Lines 1609 and 1610 - No reason documented was removed from the algorithm for both Reason Thrombolytics not Administered and Reason Primary
PCI not Performed.
6. Detail Lines 1376, 1742 and 2057 - The denominator now includes only those patients that received a red blood cell infusion instead of those that had a red
blood infusion and a CABG related transfusion.
7. Detail Lines 1264, 1268, 1272 and 1276 - There is no check in the data collection tool to verify that if First ECG Obtained is Pre-Hospital or After 1st Hospital
Arrival that the First ECG Date/Time is prior to or after Arrival Date/Time. If first ECG obtained pre hospital is selected however the First ECG Date/Time is after
the Arrival Date/Time a negative number will be calculated. This can be corrected by changing the First ECG obtained to After 1st hospital arrival or changing
First ECG Date/Time prior to Arrival Date/Time.
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
3
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Inclusion Summary
Frequently used terminology:
R4Q (Rolling Four Quarters)
The four (4) consecutive quarters included in this report. (Example: The 2011Q1 report includes
2010Q2, 2010Q3, 2010Q4 and 2011Q1. The “Q” in ‘R4Q” indicates the last quarter of the rolling
four quarters).
Benchmark Inclusion Status
Indicates whether a submission will be included in the R4Q aggregated data (benchmark) and
comparison group statistics. “Green,” “Yellow” and “Red” stoplights denote the status.
A “Green” status indicates the submission (one quarter/timeframe) is included in the benchmark
and comparison group statistics. The data has successfully passed all data assessment and
completeness checks.
A “Yellow” status indicates the submission (one quarter/timeframe) is not included in the
benchmark and comparison group statistics. Data is displayed in the quarterly column, but is not
included in the “My Hospital R4Q” summary. The data has not passed the overall completeness
assessment checks.
A “Red” status indicates the submission (one quarter/timeframe) is not included in the benchmark
or comparison group statistics. Data is not displayed in the quarterly column.
A null or blank status indicates no submission has been received for that quarter/timeframe. Data
is not displayed in the quarterly column.
Submission Type
Indicates the Submission Type selected at the time of data export/submission. “Limited”
submissions refer to the “ACTION Registry–GWTG” Limited dataset. “Premier” submissions refer
to the full ACTION dataset.
My Hospital R4Q
The values for a metric/measure (over R4Q) of data submitted by your facility with a Benchmark
Inclusion Status of “Green”.
US Hospital 50th Pctl
The median (or midpoint or 50th percentile) of all US participants’ aggregated data for the metric
or measure. Half of all participants will be above the median, and half will be below. This value will
correspond to the midpoint of the box/whisker plot with a Benchmark Inclusion Status of “Green”.
US Hospital 90th Pctl
The 90th percentile of all US participants’ aggregated data for the metric or measure. 10% of all
participants will be above the 90th percentile value, and 90% will be below. This value will
correspond to the right-most endpoint of the box/whisker plot with a Benchmark Inclusion Status
of “Green”.
US Registry Pts R4Q
The aggregated value for the measure/metric across all US patients (over R4Q). To be included,
data must have a Benchmark Inclusion Status of “Green.”
Comparison Group Pts R4Q
ACTION-GWTG™ sites with same on-site cardiac facilities (cath lab and open-heart surgery) as
your hospital, based on AHA-reported data.
Comparison Group 2
No Cardiac Services are performed at your facility, or only Diagnostic Catheterizations (No PCIs, or
open-heart surgeries).
US Participants: Compared against all US Participants where no cath lab services or Diagnostic
cath (only) services are performed on-site.
International Participants: Compared against all US Participants where no cath lab services or
Diagnostic cath (only) services are performed on-site. Indicator ‘X’ is a representation of where
your hospital would fall in the US distribution.
Comparison Group 3
Diagnostic Cath and PCIs performed on site. Adult Cardiac Interventions and diagnostic
catheterizations are performed at your facility, but not open-heart surgery.
US Participants: Compared against all US Participants where Diagnostic Cath and PCIs are
performed on site.
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
4
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Inclusion Summary
International Participants: Compared against all US Participants where Diagnostic Cath and PCIs
are performed on site. Indicator ‘X’ is a representation of where your hospital would fall in the US
distribution.
Comparison Group 4
Diagnostic Cath, PCIs and Cardiac Surgery performed on site. All cardiac procedures are
performed at your facility, to include diagnostic catheterizations, PCIs, and open-heart surgery.
US Participants: Compared against US (Region 1) Participants where Diagnostic Cath, PCIs and
Cardiac Surgery are performed on site. Region 1 includes facilities in Maine, New Hampshire,
Vermont, Massachusetts, Rhode Island, Connecticut, New York, Pennsylvania, and New Jersey.
International Participants: Compared against all US participants (not Region specific) where
Diagnostic Cath, PCIs and Cardiac Surgery are performed on site. Indicator ‘X’ in box-whisker is a
representation of where your hospital would fall in the US distribution.
Comparison Group 5
Diagnostic Cath, PCIs and Cardiac Surgery performed on site. All cardiac procedures are
performed at your facility, to include diagnostic catheterizations, PCIs, and open-heart surgery.
US Participants: Compared against US (Region 2) Participants where Diagnostic Cath, PCIs and
Cardiac Surgeries are performed on site. Region 2 includes facilities in Delaware, Maryland, District
of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky,
Mississippi, Alabama, Oklahoma, Texas, Arkansas, and Louisiana.
International Participants: Comparison Group 4 is not applicable.
Comparison Group 6
Diagnostic Cath, PCIs and Cardiac Surgery performed on site. All cardiac procedures are
performed at your facility, to include diagnostic catheterizations, PCIs, and open-heart surgery.
US Participants: Compared against US (Region 3) Participants where Diagnostic Cath, PCIs and
Cardiac Surgeries are performed on site. Region 3 includes facilities in Wisconsin, Michigan,
Illinois, Indiana, Ohio, Missouri, North Dakota, South Dakota, Nebraska, Kansas, Minnesota, and
Iowa
International Participants: Comparison Group 5 is not applicable.
Comparison Group 7
Diagnostic Cath, PCIs and Cardiac Surgery performed on site. All cardiac procedures are
performed at your facility, to include diagnostic catheterizations, PCIs, and open-heart surgery.
US Participants: Compared against US (Region 4) Participants where Diagnostic Cath, PCIs and
Cardiac Surgeries are performed on site. Region 4 includes facilities in Idaho, Montana, Wyoming,
Nevada, Utah, Colorado, Arizona, New Mexico, Alaska, Washington, Oregon, California, and
Hawaii.
International Participants: Comparison Group 6 is not applicable.
Note: Where a facility is not included in any of the comparison groups, due to an unmatchable AHA number,no “X” will be displayed in the
“Your Hospital's Comparison Group” column.
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Inclusion Summary
Box and Whisker Plots
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
6
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IA: Composite Measures
Distribution of Hospital Performance
STEMI/NSTEMI Composite Measures
1
10th percentile
90th percentile
Better
Overall AMI performance composite
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
94.3%
94.8%
98.9%
Includes all 11 acute and discharge performance measures. Proportion of
performance measure opportunities that were met among eligible
opportunities.
Measures include:
• Aspirin at Arrival
• Evaluation of LV Systolic Function
• Reperfusion Therapy (STEMI only)
• Time to Fibrinolytics (STEMI only)
• Time to Primary PCI (STEMI only)
• Aspirin at Discharge
• Beta Blocker at Discharge
• ACE-I or ARB for LVSD at Discharge
• Statin at Discharge
• Adult Smoking Cessation Advice
• Cardiac Rehab Referral [Detail Line:1002]
2
Overall defect free care
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
69.7%
73.8%
93.5%
The proportion of patients that receive "perfect care" based upon their
eligibility for each performance measure. If a patient fails to receive even
one therapy for which he or she is eligible, that patient fails to meet the
"defect-free" criteria and will be removed from the numerator. That patient
will still be included in the denominator however. [Detail Line:1003]
3
STEMI performance composite
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
96.6%
96.7%
99.6%
Includes all 11 acute and discharge performance measures for STEMI
patients. Proportion of performance measure opportunities that were met
among eligible opportunities.
Measures include:
• Aspirin at Arrival
• Evaluation of LV Systolic Function
• Reperfusion Therapy (STEMI only)
• Time to Fibrinolytics (STEMI only)
• Time to Primary PCI (STEMI only)
• Aspirin at Discharge
• Beta Blocker at Discharge
• ACE-I or ARB for LVSD at Discharge
• Statin at Discharge
• Adult Smoking Cessation Advice
• Cardiac Rehab Referral [Detail Line:1004]
4
NSTEMI performance composite
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
92.3%
93.6%
98.7%
Includes all 8 acute and discharge performance measures for NSTEMI
patients. Proportion of performance measure opportunities that were met
among eligible opporutnities.
Measures include:
• Aspirin at Arrival
• Evaluation of LV Systolic Function
• Aspirin at Discharge
• Beta Blocker at Discharge
• ACE-I or ARB for LVSD at Discharge
• Statin at Discharge
• Adult Smoking Cessation Advice
• Cardiac Rehab Referral [Detail Line:1005]
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
7
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IA: Composite Measures
5
Acute AMI performance composite
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
97.9%
96.4%
99.3%
Includes all 5 acute composite performance measures for all AMI patients.
Proportion of AMI patients with perfect adherence to the performance
measures among all eligible care opportunities for those patients.
Measures include:
• Aspirin at Arrival
• Evaluation of LV Systolic Function
• Reperfusion Therapy (STEMI only)
• Time to Fibrinolytics (STEMI only)
• Time to Primary PCI (STEMI only) [Detail Line:1006]
6
Discharge AMI performance composite
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
91.8%
94.3%
99.2%
Includes all 6 discharge performance measures for all AMI patients.
Proportion of performance measure opportunities that were met among
eligible opporutnities.
Measures include:
• Aspirin at Discharge
• Beta Blocker at Discharge
• ACE-I or ARB for LVSD at Discharge
• Statin at Discharge
• Adult Smoking Cessation Advice
• Cardiac Rehab Referral [Detail Line:1007]
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
8
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IB: Composite Measures Graphs
Overall AMI Performance Composite: 2011Q3 - 2012Q2
100.0%
Overall Defect Free Care: 2011Q3 - 2012Q2
My Hospital
Comparison Group
US Hospitals
90th = 99%
98.0%
100.0%
90.0%
96.0%
80.0%
94.0%
70.0%
92.0%
60.0%
90.0%
50.0%
88.0%
40.0%
86.0%
Hospital
Score
2011Q3
2011Q4
2012Q1
2012Q2
87.6%
93.4%
94.7%
98.5%
30.0%
Hospital
Score
STEMI Performance Composite: 2011Q3 - 2012Q2
100.0%
2011Q3
2011Q4
2012Q1
2012Q2
35.5%
61.7%
73.2%
92.6%
NSTEMI Performance Composite: 2011Q3 - 2012Q2
My Hospital
Comparison Group
US Hospitals
90th = 100%
98.0%
My Hospital
Comparison Group
US Hospitals
90th = 93%
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 99%
98.0%
96.0%
96.0%
94.0%
94.0%
92.0%
92.0%
90.0%
90.0%
88.0%
Hospital
Score
88.0%
2011Q3
2011Q4
2012Q1
2012Q2
89.3%
96.5%
97.6%
98.5%
86.0%
Hospital
Score
Acute AMI Performance Composite: 2011Q3 - 2012Q2
100.0%
2011Q4
2012Q1
2012Q2
86.5%
92.1%
92.1%
98.5%
Discharge AMI Performance Composite: 2011Q3 - 2012Q2
My Hospital
Comparison Group
US Hospitals
90th = 99%
99.0%
2011Q3
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 99%
98.0%
96.0%
98.0%
94.0%
97.0%
92.0%
96.0%
90.0%
95.0%
88.0%
94.0%
93.0%
Hospital
Score
86.0%
2011Q3
2011Q4
2012Q1
2012Q2
93.2%
97.3%
99.3%
99.3%
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
84.0%
Hospital
Score
Rev: 5
9
2011Q3
2011Q4
2012Q1
2012Q2
84.2%
90.9%
91.6%
97.9%
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IIA: AMI Performance Measures
Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, Ho PM, Kosiborod MN, Masoudi FM, Nallamothu BK.
ACC/AHA 2008 performance measures for adults with ST-elevation and non–ST-elevation myocardial infarction: a report of the
American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop
Performance Measures for ST-Elevation and Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008;52:2046 –99
Distribution of Hospital Performance
10th percentile
STEMI/NSTEMI Performance Measures
90th percentile
Better
7
Aspirin at arrival
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
97%
99.3%
100.0%
Proportion of patients prescribed aspirin at arrival excluding patients
transferred in and out. [Detail Line:1009]
8
Aspirin prescribed at discharge
My Hospital
US Hospitals 50th Pctl
99.3%
99.1%
US Hospitals 90th Pctl
100.0%
Proportion of patients prescribed aspirin at discharge. [Detail Line:1010]
9
Beta-blocker prescribed at discharge
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
99.4%
97.9%
100.0%
Proportion of patients prescribed a beta-blocker at discharge. [Detail Line:
1011]
10
Statin prescribed at discharge
My Hospital
US Hospitals 50th Pctl
100%
99.1%
US Hospitals 90th Pctl
100.0%
Proportion of patients prescribed a statin at discharge. [Detail Line:1012]
11
Evaluation of LV systolic function
My Hospital
US Hospitals 50th Pctl
99.4%
96.1%
US Hospitals 90th Pctl
100.0%
Proportion of patients evaluated for LV systolic function. [Detail Line:1013]
12
ACE-I or ARB for LVSD at discharge
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
85%
91.8%
100.0%
Proportion of patients prescribed an ACE-I or ARB for LVSD at discharge.
[Detail Line:1014]
13
Proportion of STEMI patients receiving fibrinolytics within 30
minutes
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
23.8%
100.0%
Proportion of STEMI patients with a time from your hospital arrival (or
subsequent ECG if ST elevation first noted on subsequent ECG) to
fibrinolytics <= 30 minutes. [Detail Line:1015]
14
Median time in minutes to fibrinolytic therapy for STEMI patients
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
36.5
15.6
Your hospital's median time in minutes from hospital arrival to fibrinolytics
for STEMI patients. [Detail Line:1016]
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
10
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IIA: AMI Performance Measures
Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, Ho PM, Kosiborod MN, Masoudi FM, Nallamothu BK.
ACC/AHA 2008 performance measures for adults with ST-elevation and non–ST-elevation myocardial infarction: a report of the
American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop
Performance Measures for ST-Elevation and Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008;52:2046 –99
15
Proportion of STEMI patients receiving primary PCI within 90
minutes
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
93.7%
96.1%
100.0%
Proportion of STEMI patients with a time from your hospital arrival (or
subsequent ECG if ST elevation first noted on subsequent ECG) to primary
PCI <= 90 minutes. [Detail Line:1017]
16
Median Time in minutes to primary PCI for STEMI patients
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
61
60.0
48.5
Your hospital's median time in minutes from hospital arrival to primary PCI
for STEMI patients. [Detail Line:1018]
17
Reperfusion therapy
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
100%
98.8%
100.0%
Proportion of STEMI patients that received either fibrinolytics or a primary
PCI. [Detail Line:1019]
18
Time in minutes from ED arrival at STEMI referral facility to ED
discharge from STEMI referral facility in patients transferred for
PCI (1)
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
35
47.2
29.6
Your hospital's median time in minutes from ED arrival at referral facility to
ED discharge at referral facility among patients transferred for a primary
PCI. [Detail Line:1020]
Low Volume Alert
19
Time in minutes from ED arrival at STEMI referral facility to
Primary PCI at STEMI receiving facility among transferred patients
(1)
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
76.5
108.3
81.8
Your hospital's median time in minutes from arrival at STEMI referring
facility to primary PCI at STEMI receiving facility among patients transferred
for a primary PCI. [Detail Line:1021]
Low Volume Alert
20
Adult smoking cessation advice counseling
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
100%
100.0%
100.0%
Proportion of patients that received smoking cessation advice/counseling
among those that have smoked within the past year. [Detail Line:1022]
21
Cardiac rehabilitation patient referral from an inpatient setting
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
67.1%
84.1%
99.2%
Proportion of patients that received a cardiac rehab referral. [Detail Line:
1023]
Executive Summary Footnotes
1
IMPORTANT INTERPRETATION NOTE: Median times by quarter are plotted in the graph, thus downward slope indicates improvement as shorter times are preferable
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
11
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IIB: AMI Performance Measures Graphs
Aspirin at Arrival: 2011Q3 - 2012Q2
100.0%
Aspirin at Discharge: 2011Q3 - 2012Q2
My Hospital
Comparison Group
US Hospitals
90th = 100%
98.0%
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 100%
99.5%
99.0%
96.0%
98.5%
94.0%
98.0%
97.5%
92.0%
97.0%
90.0%
88.0%
Hospital
Score
96.5%
2011Q3
2011Q4
2012Q1
89.7%
97.9%
97.9%
96.0%
2012Q2
100.0%
Hospital
Score
2011Q3
96.4%
Beta Blocker at Discharge: 2011Q3 - 2012Q2
100.0%
100.0%
2012Q1
100.0%
2012Q2
100.0%
Statin at Discharge: 2011Q3 - 2012Q2
My Hospital
Comparison Group
US Hospitals
90th = 100%
99.5%
2011Q4
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 100%
98.0%
99.0%
98.5%
96.0%
98.0%
94.0%
97.5%
97.0%
92.0%
96.5%
96.0%
Hospital
Score
2011Q3
96.4%
2011Q4
2012Q1
100.0%
100.0%
90.0%
2012Q2
100.0%
Hospital
Score
Evaluation of LV Systolic Function: 2011Q3 - 2012Q2
100.0%
100.0%
2011Q4
100.0%
2012Q1
100.0%
2012Q2
100.0%
ACE-I or ARB for LVSD at Discharge: 2011Q3 - 2012Q2
My Hospital
Comparison Group
US Hospitals
90th = 100%
99.0%
2011Q3
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 100%
96.0%
92.0%
98.0%
88.0%
97.0%
84.0%
96.0%
95.0%
Hospital
Score
80.0%
2011Q3
100.0%
2011Q4
2012Q1
97.7%
100.0%
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
76.0%
2012Q2
100.0%
Hospital
Score
Rev: 5
12
2011Q3
100.0%
2011Q4
2012Q1
85.7%
77.8%
2012Q2
100.0%
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IIB: AMI Performance Measures Graphs
Time to Fibrinolytics <= 30 mins (STEMI): 2011Q3 - 2012Q2
100.0%
Time to Primary PCI <= 90 mins (STEMI): 2011Q3 - 2012Q2
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 100%
90.0%
80.0%
92.0%
88.0%
70.0%
84.0%
60.0%
80.0%
50.0%
76.0%
40.0%
30.0%
My Hospital
Comparison Group
US Hospitals
90th = 100%
96.0%
72.0%
2011Q3
2011Q4
2012Q1
68.0%
2012Q2
Hospital
Score
Hospital
Score
2011Q3
2011Q4
2012Q1
2012Q2
71.4%
90.9%
100.0%
96.0%
Reperfusion Therapy (STEMI): 2011Q3 - 2012Q2
Door in to Door Out (STEMI): 2011Q3 - 2012Q2
My Hospital
Comparison Group
US Hospitals
90th = 100%
98.0%
96.0%
94.0%
92.0%
64
My Hospital
Comparison Group
US Hospitals
90th = 29.6
60
Median Time in Mins
100.0%
56
52
48
44
40
36
32
28
90.0%
Hospital
Score
2011Q3
100.0%
2011Q4
2012Q1
2012Q2
100.0%
100.0%
100.0%
24
Door in to PCI (STEMI): 2011Q3 - 2012Q2
115
Median Time in Mins
105
2011Q4
2012Q1
2012Q2
60
33.5
Adult Smoking Cessation Advice: 2011Q3 - 2012Q2
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 81.8
110
2011Q3
Hospital
Score
My Hospital
Comparison Group
US Hospitals
90th = 100%
98.0%
100
96.0%
95
90
94.0%
85
80
92.0%
75
70
2011Q3
2011Q4
2012Q1
2012Q2
102.5
76
Hospital
Score
90.0%
Hospital
Score
2011Q3
100.0%
2011Q4
2012Q1
2012Q2
100.0%
100.0%
100.0%
Cardiac Rehab. Referral: 2011Q3 - 2012Q2
100.0%
My Hospital
Comparison Group
US Hospitals
90th = 99%
90.0%
80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
Hospital
Score
2011Q3
2011Q4
2012Q1
2012Q2
37.9%
65.1%
65.9%
90.5%
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
13
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section III: Quality Metrics
Distribution of Hospital Performance
10th percentile
Quality Metrics
22
Door to 1st ECG in minutes
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
64.1%
65.0%
83.9%
Proportion of AMI patients that received an ECG within 10 minute of arrival
at participating hospital. [Detail Line:1025]
23
Acute ADP receptor inhibitor therapy among STEMI patients
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
100%
94.8%
100.0%
Proportion of STEMI patients prescribed ADP Receptor Inhibitors 24 hours
prior to or after 1st hospital arrival. [Detail Line:1026]
24
Acute anticoagulant agent for NSTEMI
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
94.2%
100.0%
Proportion of NSTEMI patients prescribed unfractionated heparin,
enoxaparin, bivalirudin or fondaparinux 24 hours prior to or after 1st
hospital arrival. [Detail Line:1027]
25
Excessive initial unfractionated heparin (UFH) dose
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
61.7%
12.8%
Proportion of AMI patients that received:
-An initial bolus dose of UFH >70 units per kilogram OR
-A total initial bolus dose exceeding 4000 units OR
-An initial infusion > 15 units per kilogram per hour OR
-A total initial infusion >1000 units per hour. [Detail Line:1028]
26
Excessive initial enoxaparin dose
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
9.4%
0.0%
Proportion of AMI patients that received an initial dose of subcutaneous
Enoxaparin >1.05 mg per kilogram. [Detail Line:1029]
27
Excessive initial GPIIb-IIIa inhibitor therapy
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
6.2%
0.0%
Proportion of AMI patients that received GPIIb-IIIa (Full dose of Tirofiban if
CrCL <30 cc/min and/or dialysis = yes or full dose of Eptifibatide if CrCL
<50 cc//min and /or dialysis = yes) [Detail Line:1030]
28
AMI revascularized patients discharged on ADP receptor inhibitors
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
91.1%
93.5%
100.0%
Proportion of AMI revascularized patients prescribed an ADP receptor
inhibitor at discharge. [Detail Line:1031]
29
ADP receptor inhibitors prescribed at discharge for medically
treated AMI patients
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
59.1%
55.5%
80.0%
Proportion of AMI medically treated patients prescribed an ADP receptor
inhibitor at discharge. [Detail Line:1032]
30
Aldosterone blocking agents for LVSD at discharge
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
0%
7.8%
37.8%
Proportion of AMI patients prescribed an aldosterone blocking agent at
discharge. [Detail Line:1033]
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
90th percentile
Better
Rev: 5
14
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section III: Quality Metrics
31
LDL-Cholesterol assessment
My Hospital
US Hospitals 50th Pctl
US Hospitals 90th Pctl
67.7%
85.0%
95.7%
Proportion of patients that had an LDL-Cholesterol assessment. [Detail Line:
1034]
32
Aspirin at arrival for all patients
My Hospital
US Hospitals 50th Pctl
97.8%
99.1%
US Hospitals 90th Pctl
100.0%
Proportion of patients that received an aspirin on arrival. [Detail Line:1035]
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
15
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Section IV: Participant Graphs
Site Admission Trend
US Admission Trend
45
STEMI
NSTEMI
25,000
STEMI
NSTEMI
40
20,000
30
15,000
Admissions
Admissions
35
25
20
10,000
15
5,000
10
5
2011Q3
2011Q4
2012Q1
0
2012Q2
2011Q3
Distribution of Patient Age
50.0%
Percent of Admissions
Percent of Admissions
43%
22%
20.0%
18% 18%
17%
16.0%
12%
12.0%
12%
10%
10%
9%
40.0%
30.0%
28%
20.0%
29%
17%
7%
6%
0.0%
Hospital
US
56%
26%
24.0%
4.0%
2012Q2
60.0%
29%
8.0%
2012Q1
Distribution of Race and Gender
Hospital
US
32.0%
28.0%
2011Q4
10.0%
11%
9%
3%
18-44
6%
45-54
55-64
65-69
70-74
75-79
0.0%
>= 80
Male/White
Male/Non White
Female/White
Female/Non White
Time from Symptom Onset to Hospital Presentation
Hospital
US
ECG w/in 10 Minutes of Presentation
80.0%
Hospital
US
Percent of Admissions
72.0%
68.0%
2.01
75%
76.0%
2.00
70%
68%
67%
2.00
64.0%
2.00
2.00
2.01
60.0%
57%
56.0%
Time from Hospital Presentation to ECG
56%
54%
52.0%
Hospital
US
8.00
48.0%
45%
44.0%
40.0%
2.01
Median Hours
7.00
Male
Female
<75 years
75+ years
6.80
7.20
7.60
8.00
8.40
Median Minutes
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
16
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Acute Medications (w/in 24h of Hospital Presentation)
100.0%
97%
98%
In-Hospital Procedures
Hospital
US
90.0%
80.0%
70.0%
60.0%
55%
Percent of Admissions
Percent of Admissions
80.0%
54%
40.0%
34%
65%
65%
60.0%
50.0%
40.0%
30.0%
20.0%
20.0%
10%
0.0%
Aspirin
Clopidogrel
10.0%
0.0%
GP IIb/IIIa
Diag Cor Angio
70.0%
PCI
CABG
Reperfusion Use
Hospital
US
71%
9%
6%
Drug Eluting vs Bare Metal Stents
75.0%
102.0%
69%
65.0%
98.0%
60.0%
96.0%
55.0%
50.0%
45.0%
40.0%
35.0%
Hospital
US
100%
100.0%
Percent of Admissions
Percent of Admissions
Hospital
US
86%
82%
97%
97%
94.0%
92.0%
90.0%
88.0%
86.0%
32%
30.0%
29%
25.0%
DES
84.0%
82.0%
Bare Metal
84%
Reperfusion
85%
Transfers in
84%
Non-Transfers in
In-Hospital Antithrombin Medications
80.0%
Hospital
US
70%
70.0%
61%
Percent of Admissions
60.0%
51%
50.0%
40.0%
39%
33%
32%
30.0%
20.0%
10.0%
0.0%
7%
0%
UFH
LMWH
Fondaparinux
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
1%
0%
DTI
Thrombolytics
Rev: 5
17
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
First Medical Contact to ECG to Hospital Arrival to Needle
(Pre-Hospital ECG)
FMC to ECG
ECG to arrival
Arrival to needle
US
12
0
17
10
First Medical Contact to Hospital Arrival to ECG to Needle
(ECG After Hospital Arrival)
FMC to arrival
Arrival to ECG
ECG to needle
US
30
20
30
40
50
60
33
0
10
0
20
Minutes
16
30
40
50
Minutes
First Medical Contact to ECG to Hospital Arrival to Balloon
(Pre-Hospital ECG)
First Medical Contact to Hospital Arrival to ECG to Balloon
(ECG After Hospital Arrival)
FMC to arrival
Arrival to ECG
ECG to balloon
FMC to ECG
ECG to arrival
Arrival to balloon
Hospital 4
US
21
7
0
22
10
Hospital
51
20
US
47
30
40
50
60
70
0
30
0
80
10
60.5
2
20
30
58
40
50
60
70
80
90
Minutes
Minutes
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
22
Rev: 5
18
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Early Catheterization by Subgroups
Time from Hospital Presentation to Procedure
80.0%
74%
74%
74%
70%
70.0%
Hospital
US
67%
Cath
64%
3.5
60.0%
Percent of Admissions
Hospital
US
50.0%
1.4
PCI
40.0%
1.7
30.0%
20.0%
CABG
68.5
10.0%
0.0%
0%
0%
Male
Female
0%
0%
<75 years
75+ years
0%
0%
<50 cc/min
0.0
10.0
20.0
30.0
In-hospital Clinical Events
8.0%
50.0
60.0
70.0
Length of Stay
Hospital
US
7%
40.0
Median Hours
50+ cc/min
Hospital
US
3.0
Overall
7.0%
3.0
Percent of Admissions
6.0%
Early Cath
5.0%
3.0
4%
4.0%
2.0
Any PCI
3.0%
3%
2.0%
3.0
2%
10.0
Any CABG
1.0%
0.0%
1%
1%
9.0
1%
0%
Reinfarction
0.0
Shock
CVA/Stroke
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Death
2.0
4.0
6.0
8.0
10.0
Median Days
Rev: 5
19
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
ACTION Registry®-GWTG™
Sample Hospital compared to Rolling Four Quarters (R4Q) for US Hospitals ending 2012Q2
Bleeding Events Among Subgroups
6.0%
Dosing Errors
Hospital
US
50.0%
45.0%
5%
5.0%
40.0%
4%
3.0%
3%
3%
Percent of Admissions
Percent of Admissions
4%
4.0%
Hospital
US
48%
3%
2.0%
35.0%
30.0%
25.0%
20.0%
15.0%
12%
1%
10.0%
1.0%
7%
1%
1%
5.0%
0.0%
0%
0%
Male
Female
0%
0.0%
<75 years 75+ years <50 cc/min 50+ cc/min
UFH (AMI)
Discharge Medications
99%
Hospital
US
99%
98%
120.0%
97%
Hospital
US
100%
100.0%
95.0%
Percent of Admissions
Percent of Admissions
85%
90.0%
85.0%
80.0%
75.0%
70.0%
65.0%
63%
GP IIb/IIIa (AMI)
Discharge Medications
105.0%
100.0%
Enox (AMI)
80.0%
76%
99%
89%
73%
60.0%
40.0%
20.0%
62%
11%
60.0%
0.0%
55.0%
Aspirin
Clopidogrel
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Beta Blocker
Rev: 5
20
0%
ACE/ARB Overall ACE/ARB Ideal
Statin
Other Lipid
Lowering
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Detail Section Line Reference
Population
Section
First Line #
Last Line #
Executive Summary
Detail Lines
1000
1035
All Patients
Submission Summary
1036
1043
Demographics and Payors
1044
1078
Medical History/Home Medications
1079
1112
Hospital Presentation
1113
1156
Acute and In-Hospital Medications and
Dosing Errors
1157
1202
In-Hospital Procedures
1203
1231
Reperfusion Use
1232
1277
Early Invasive Management
1278
1302
Laboratory Results
1303
1325
In-Hospital Events
1326
1347
Bleeding Events
1348
1376
Discharge Therapies
1377
1413
Length of stay
1414
1419
Demographics and Payors
1420
1454
Medical History/Home Medications
1455
1488
Hospital Presentation
1489
1527
Acute and In-Hospital Medications and
Dosing Errors
1528
1573
In-Hospital Procedures
1574
1602
Reperfusion Use
1603
1647
Early Invasive Management
1648
1668
Laboratory Results
1669
1691
In-Hospital Events
1692
1713
Bleeding Events
1714
1742
Discharge Therapies
1743
1778
Demographics and Payors
1779
1813
Medical History/Home Medications
1814
1847
Hospital Presentation
1848
1884
Acute and In-Hospital Medications and
Dosing Errors
1885
1930
In-Hospital Procedures
1931
1959
Reperfusion Use
1960
1962
Early Invasive Management
1963
1983
Laboratory Results
1984
2006
In-Hospital Events
2007
2028
Bleeding Events
2029
2057
Discharge Therapies
2058
2093
Acute Therapies by Race
2094
2112
Discharge Therapies by Race
2113
2128
Acute and Discharge Therapies by
Gender
2129
2159
Acute and Discharge Therapies by Age
2160
2190
Acute and Discharge Therapies by
Transfer Status
2191
2214
Acute and Discharge Therapies by
Diabetes Status
2215
2238
Acute and Discharge Therapies by
Creatinine Clearance
2239
2267
STEMI Patients
NSTEMI Patients
Overall AMI Subgroups
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
21
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Executive Summary
Detail Lines
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1000
Executive Summary Detail
Lines
1001
Composites
1002
Overall AMI Performance
Composite
176
201
87.6
268
287
93.4
1003
Overall Defect Free Care
11
31
35.5
29
47
61.7
1004
STEMI Performance Composite
67
75
89.3
82
85
96.5
1005
NSTEMI Performance
Composite
109
126
86.5
186
202
92.1
1006
Acute AMI Performance
Composite
69
74
93.2
108
111
1007
Discharge AMI Performance
Composite
107
127
84.3
160
176
1008
Performance measures
1009
Aspirin at arrival
26
29
89.7
46
1010
Aspirin prescribed at discharge
27
28
96.4
40
1011
Beta-blocker prescribed at
discharge
27
28
96.4
1012
Statin prescribed at discharge
28
28
1013
Evaluation of LV systolic
function
29
29
1014
ACEI or ARB for LVSD at
Discharge
3
3
1015
Time to Fibrinolytic Therapy
1016
Median time to fibrinolytic
therapy
1017
Time to primary PCI
1018
Median time to primary PCI
1019
Reperfusion therapy
1020
Median time to Door in door
out transfer in patients (1)
1021
Median time to Door to balloon
transfer in patients (1)
1022
Adult smoking cessation advice
counseling
11
11
100.0
8
8
100.0
17
17
100.0
16
16
100.0
52
52
100.0
3,311
98.2
40,868
98.5
1023
Cardiac rehabilitation patient
referral from an inpatient
setting
11
29
37.9
28
43
65.1
29
44
65.9
38
42
90.5
106
158
67.1
7,022
69.7
80,063
77.8
1024
Quality metrics
1025
Door to 1st ECG
18
25
72.0
20
37
54.1
17
28
60.7
20
27
74.1
75
117
64.1
4,101
64.8
41,719
63.4
1026
Acute ADP receptor inhibitor
9
9
100.0
10
10
100.0
18
18
100.0
22
22
100.0
59
59
100.0
2,987
94.0
26,620
93.2
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Num
Den
%
Num
Den
%
Num
Den
323
%
341
94.7
41
56
73.2
160
164
97.6
163
177
92.1
97.3
137
138
90.9
186
203
47
97.9
47
40
100.0
41
39
39
100.0
100.0
39
39
100.0
42
43
100.0
6
7
Num
Den
331
%
Num
Den
%
336
98.5
1,098
1,165
94.3
50
54
92.6
131
188
201
204
98.5
510
528
130
132
98.5
588
99.3
144
145
99.3
91.6
187
191
48
97.9
45
41
100.0
43
44
44
100.0
100.0
48
48
97.7
49
49
85.7
7
9
Num
US Registry Pts
R4Q
%
68,670
93.3
69.7
8,015
96.6
32,689
637
92.3
458
468
97.9
640
45
100.0
43
100.0
44
44
100.0
45
100.0
46
77.8
1
5
7
71.4
9
10
11
90.9
65.0
9
100.0
10
20
20
100.0
61.5
10
100.0
24
94.4
66.0
86,385
71.4
95.4
325,574
95.9
35,981
91.6
377,162
93.0
97.9
25,840
96.0
251,838
96.1
697
91.8
42,830
91.8
450,898
93.4
164
169
97.0
8,084
98.4
77,633
98.2
151
152
99.3
10,231
98.7
102,172
98.4
100.0
154
155
99.4
10,404
97.3
105,866
97.1
45
100.0
160
160
100.0
10,529
98.9
105,094
98.6
46
100.0
166
167
99.4
10,850
94.2
109,338
95.0
1
100.0
17
20
85.0
1,333
90.2
16,835
89.3
4
50.0
79
52.7
25
96.0
51.0
21
21
100.0
29
%
702,736
31.0
83.0
Num
59
63
93.7
61.0
29
100.0
69
2,798
29.5
94.5
59.0
69
100.0
4,104
25,075
97.3
39,713
60.0
33.5
35.0
43.0
45.0
102.5
76.0
76.5
101.0
105.0
Rev: 5
94.6
58.0
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
96.4
Executive Summary
Detail Lines
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
therapy among STEMI patients
1027
Acute anticoagulant agent for
NSTEMI
3,235
94.1
34,856
93.0
1028
Excessive initial unfractionated
heparin (UFH) dose
1,000
49.9
11,373
48.1
1029
Excessive initial enoxaparin
dose
192
14.7
1,901
11.5
1030
Excessive initial GPIIb-IIIa
inhibitor therapy
123
5.5
2,024
7.1
1031
AMI revascularized patients
discharged on ADP receptor
inhibitors
1032
18
18
100.0
27
29
93.1
26
29
89.7
31
36
86.1
102
112
91.1
7,102
89.8
70,178
91.1
ADP receptor inhibitors
prescribed at discharge for
medically treated AMI patients
8
11
72.7
6
11
54.6
7
15
46.7
5
7
71.4
26
44
59.1
1,295
51.6
14,474
55.6
1033
Aldosterone blocking agents for
LVSD at discharge
0
5
0.0
0
3
0.0
0
8
0.0
0
2
0.0
0
18
0.0
183
19.2
1,770
15.2
1034
LDL-cholesterol assessment
19
29
65.5
30
43
69.8
31
49
63.3
33
46
71.7
113
167
67.7
9,187
80.7
94,142
82.8
1035
Aspirin at arrival for all patients
26
28
92.9
45
46
97.8
53
54
98.2
54
54
100.0
178
182
97.8
11,133
98.5
112,336
98.3
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Submission Summary
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1036
Submission summary
1037
Total # of pt admissions
1038
STEMI
1039
NSTEMI
1040
Transfers in
1041
Not Transferred in
1042
Transfers out
1043
Not transferred out
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Num
Den
%
32
Num
Den
%
53
Num
Den
%
63
Num
Den
%
59
Num
Den
%
207
Num
US Registry Pts
R4Q
%
13,040
Num
%
130,124
9
32
28.1
11
53
20.8
26
63
41.3
30
59
50.9
76
207
36.7
5,245
40.2
50,604
38.9
23
32
71.9
42
53
79.3
37
63
58.7
29
59
49.2
131
207
63.3
7,795
59.8
79,520
61.1
0
32
0.0
0
53
0.0
5
63
7.9
6
59
10.2
11
207
5.3
3,480
26.7
37,637
28.9
32
32
100.0
53
53
100.0
58
63
92.1
53
59
89.8
196
207
94.7
9,560
73.3
92,487
71.1
1
32
3.1
2
53
3.8
6
63
9.5
8
59
13.6
17
207
8.2
360
2.8
5,533
4.3
30
32
93.8
45
53
84.9
52
63
82.5
47
59
79.7
174
207
84.1
12,026
92.2
118,785
91.3
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Demographics and Payors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1044
Demographics
1045
Sex
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1046
Male
15
32
46.9
30
53
56.6
41
63
65.1
40
59
67.8
126
207
60.9
8,645
66.3
84,349
64.8
1047
Female
17
32
53.1
23
53
43.4
22
63
34.9
19
59
32.2
81
207
39.1
4,395
33.7
45,775
35.2
1048
Age at admission
1049
Mean age
65
69
68
65
67
66
1050
Median age
67
71
63
64
64
65
1051
18-44
2
32
6.3
1
53
1.9
2
63
3.2
2
59
3.4
7
207
3.4
744
5.7
9,155
7.0
1052
45-54
6
32
18.8
12
53
22.6
10
63
15.9
9
59
15.3
37
207
17.9
2,026
15.5
23,530
18.1
1053
55-64
7
32
21.9
9
53
17.0
21
63
33.3
23
59
39.0
60
207
29.0
3,507
26.9
34,413
26.5
1054
65-69
2
32
6.3
3
53
5.7
6
63
9.5
10
59
17.0
21
207
10.1
1,661
12.7
15,979
12.3
1055
70-74
5
32
15.6
3
53
5.7
2
63
3.2
2
59
3.4
12
207
5.8
1,403
10.8
13,330
10.2
1056
75-79
3
32
9.4
9
53
17.0
8
63
12.7
4
59
6.8
24
207
11.6
1,244
9.5
11,660
9.0
1057
>= 80
7
32
21.9
16
53
30.2
14
63
22.2
9
59
15.3
46
207
22.2
2,455
18.8
22,057
17.0
17
32
53.1
31
53
58.5
30
63
47.6
25
59
42.4
103
207
49.8
6,763
51.9
63,026
48.4
1058
1059
Medicare age ( >= 65)
65
64
Race
1060
White
27
32
84.4
37
53
69.8
42
63
66.7
42
59
71.2
148
207
71.5
11,400
87.4
110,766
85.1
1061
Black/African American
4
32
12.5
4
53
7.6
13
63
20.6
13
59
22.0
34
207
16.4
477
3.7
15,221
11.7
1062
Asian
1
32
3.1
6
53
11.3
5
63
7.9
4
59
6.8
16
207
7.7
727
5.6
2,466
1.9
1063
American Indian/Alaskan
0
32
0.0
0
53
0.0
1
63
1.6
0
59
0.0
1
207
0.5
118
0.9
754
0.6
1064
Hawaiian/Pacific Islander
0
32
0.0
3
53
5.7
2
63
3.2
0
59
0.0
5
207
2.4
83
0.6
216
0.2
1065
Male/White
13
32
40.6
21
53
39.6
27
63
42.9
29
59
49.2
90
207
43.5
7,577
58.1
72,805
56.0
1066
Male/Non White
2
32
6.3
9
53
17.0
14
63
22.2
11
59
18.6
36
207
17.4
1,068
8.2
11,544
8.9
1067
Female/White
14
32
43.8
16
53
30.2
15
63
23.8
13
59
22.0
58
207
28.0
3,823
29.3
37,961
29.2
1068
Female/Non White
1069
Hispanic or Latino Ethnicity
1070
Insurance payors
3
32
9.4
7
53
13.2
7
63
11.1
6
59
10.2
23
207
11.1
572
4.4
7,814
6.0
7
32
21.9
6
53
11.3
8
63
12.7
6
59
10.2
27
207
13.0
1,368
10.6
6,235
4.8
1071
Private
16
32
50.0
23
53
43.4
32
63
50.8
25
59
42.4
96
207
46.4
7,203
55.2
72,781
55.9
1072
Medicare
18
32
56.3
36
53
67.9
34
63
54.0
32
59
54.2
120
207
58.0
6,468
49.6
65,222
50.1
1073
Medicaid
6
32
18.8
13
53
24.5
10
63
15.9
11
59
18.6
40
207
19.3
1,366
10.5
12,810
9.8
1074
Military
0
32
0.0
4
53
7.6
2
63
3.2
6
59
10.2
12
207
5.8
651
5.0
3,824
2.9
1075
State-specific (non-Medicaid)
0
32
0.0
0
53
0.0
3
63
4.8
2
59
3.4
5
207
2.4
432
3.3
1,677
1.3
1076
Indian Health Service
0
32
0.0
0
53
0.0
0
63
0.0
0
59
0.0
0
207
0.0
26
0.2
230
0.2
1077
Non-U.S Insurance
0
32
0.0
0
53
0.0
0
63
0.0
0
59
0.0
0
207
0.0
16
0.1
113
0.1
1078
None
3
32
9.4
2
53
3.8
5
63
7.9
8
59
13.6
18
207
8.7
1,288
9.9
15,643
12.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Medical History/Home Medications
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
1079
History and risk factors
1080
Current smoker (< 1 year)
12
32
37.5
9
53
17.0
19
63
30.2
18
59
30.5
58
207
28.0
1081
Hypertension
27
32
84.4
43
53
81.1
53
63
84.1
52
59
88.1
175
207
84.5
1082
Dyslipidemia
1083
Currently on dialysis
1084
Chronic lung disease
1085
Diabetes mellitus
1086
3
32
9.4
3
53
5.7
2
63
3.2
6
59
10.2
14
207
6.8
Num
US Registry Pts
R4Q
%
Num
%
3,698
28.4
45,443
34.9
9,264
71.1
96,227
74.0
6,183
60.9
63,788
60.9
370
2.8
3,421
2.6
1,269
12.5
15,577
14.9
12
32
37.5
21
52
40.4
19
63
30.2
31
59
52.5
83
206
40.3
4,106
31.5
42,801
32.9
6.4
Diabetes therapy:
1087
None
0
12
0.0
0
21
0.0
0
19
0.0
0
31
0.0
0
83
0.0
263
6.4
2,733
1088
Diet
0
12
0.0
0
21
0.0
0
19
0.0
0
31
0.0
0
83
0.0
265
6.5
2,269
5.3
1089
Oral
0
12
0.0
0
21
0.0
0
19
0.0
0
31
0.0
0
83
0.0
1,419
34.6
16,297
38.1
1090
Insulin
0
12
0.0
0
21
0.0
0
19
0.0
0
31
0.0
0
83
0.0
1,087
26.5
12,763
29.8
1091
Other
0
12
0.0
0
21
0.0
0
19
0.0
0
31
0.0
0
83
0.0
45
1.1
201
0.5
1092
Obesity (BMI >= 30)
3,781
37.5
41,829
40.3
1093
Prior MI
2,498
24.6
26,650
25.5
1094
Prior heart failure
1,140
11.3
13,374
12.8
1095
Prior PCI
2,284
22.5
25,939
24.8
1096
Prior CABG
1,226
12.1
14,554
13.9
1097
Atrial fibrillation or flutter
(past 2 weeks)
720
7.1
7,834
7.5
1098
Cerebrovascular disease
12.0
1099
Prior stroke
1100
Peripheral arterial disease
0
32
0.0
3
53
5.7
10
63
15.9
5
59
8.5
18
207
8.7
1,440
11.1
15,582
0
32
0.0
3
53
5.7
10
63
15.9
4
59
6.8
17
207
8.2
917
7.0
10,237
7.9
3
32
9.4
4
52
7.7
5
63
7.9
5
58
8.6
17
205
8.3
1,022
7.8
12,428
9.6
1101
Home medications
1102
Aspirin
4,196
41.4
45,298
43.3
1103
Clopidogrel
1,043
10.3
14,867
14.2
1104
Ticlopidine
2
0.0
101
0.1
1105
Prasugrel
81
0.8
1,193
1.1
1106
Warfarin
478
4.7
5,182
5.0
1107
Beta blocker
3,443
33.9
40,177
38.4
1108
ACE inhibitor
2,623
25.9
30,129
28.8
1109
Angiotensin receptor
blocker
1,058
10.4
11,065
10.6
1110
Aldosterone blocking agent
1111
Statin
1112
Non-statin lipid-lowering
agent
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
209
2.1
2,333
2.2
3,956
39.0
42,109
40.2
719
7.1
9,352
8.9
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Hospital Presentation
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1113
Hospital presentation
1114
Means of transport (first
facility)
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1115
Self/family
18
32
56.3
28
53
52.8
21
63
33.3
22
59
37.3
89
207
43.0
6,825
52.4
71,268
54.8
1116
Ambulance
14
32
43.8
25
53
47.2
42
63
66.7
37
59
62.7
118
207
57.0
6,078
46.6
57,173
44.0
1117
Mobile ICU
0
32
0.0
0
53
0.0
0
63
0.0
0
59
0.0
0
207
0.0
12
0.1
699
0.5
1118
Air
0
32
0.0
0
53
0.0
0
63
0.0
0
59
0.0
0
207
0.0
122
0.9
868
0.7
73.6
1119
Means of transfer (outside
facility)
1120
Ambulance
5
5
100.0
6
6
100.0
11
11
100.0
2,207
63.7
27,634
1121
Mobile ICU
0
5
0.0
0
6
0.0
0
11
0.0
127
3.7
2,066
5.5
1122
Air
0
5
0.0
0
6
0.0
0
11
0.0
1,133
32.7
7,831
20.9
7,571
74.6
75,706
72.3
1123
1124
1125
Location of first evaluation
ED
Median hours from arrival to
transfer out from ED
1126
Cath lab
1127
Other
1128
2.3
2.7
941
9.3
12,660
12.1
1,631
16.1
16,332
15.6
First ECG obtained
1129
Pre hospital (3)
1130
After 1st hospital arrival
1131
Median time to 1st ECG (in
min)
1132
ECG <= 10 min of
presentation
1133
STEMI ECG findings
7
32
21.9
16
53
30.2
30
58
51.7
26
53
49.1
79
196
40.3
3,187
33.4
26,534
28.7
25
32
78.1
37
53
69.8
28
58
48.3
27
53
50.9
117
196
59.7
6,366
66.6
65,856
71.3
7.0
10.0
7.5
7.0
8.0
7.0
7.0
18
25
72.0
20
37
54.1
17
28
60.7
20
27
74.1
75
117
64.1
4,101
64.8
41,719
63.4
1134
ST elevation
9
9
100.0
11
11
100.0
26
26
100.0
30
30
100.0
76
76
100.0
5,079
97.0
49,014
96.9
1135
LBBB
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
132
2.5
1,118
2.2
1136
Isolated posterior MI
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
27
0.5
430
0.9
1137
STEMI first noted
1138
First ECG
6
9
66.7
8
11
72.7
25
26
96.2
26
30
86.7
65
76
85.5
4,607
88.0
43,914
86.9
1139
Subsequent ECG
3
9
33.3
3
11
27.3
1
26
3.9
4
30
13.3
11
76
14.5
626
12.0
6,624
13.1
1140
Other ECG findings
1141
New or presumed new ST
depression
4
23
17.4
7
42
16.7
5
35
14.3
5
29
17.2
21
129
16.3
1,879
24.2
15,701
19.8
1142
New or presumed new T-wave
inversion
3
23
13.0
5
42
11.9
5
35
14.3
5
29
17.2
18
129
14.0
1,212
15.6
10,324
13.0
1143
Transient ST elevation lasting
<20 min
1
23
4.4
5
42
11.9
0
35
0.0
0
29
0.0
6
129
4.7
217
2.8
1,612
2.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Hospital Presentation
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
1144
1145
Description
None
Median time from symptom
onset to presentation
(hours) (2)
1146
>= 6 hours
1147
< 6 hours
Num
Den
15
%
23
65.2
2.0
Num
Den
25
%
42
59.5
3.8
Num
Den
25
%
35
71.4
1.8
Num
Den
19
%
29
65.5
2.1
Num
Den
84
%
129
65.1
2.0
Num
US Registry Pts
R4Q
%
4,444
57.3
2.0
Num
%
51,559
65.1
2.0
8
32
25.0
19
53
35.9
17
58
29.3
14
53
26.4
58
196
29.6
1,649
19.1
14,770
18.6
24
32
75.0
34
53
64.2
41
58
70.7
39
53
73.6
138
196
70.4
6,645
76.9
60,057
75.5
1148
Cardiac status on first
medical contact
1149
Heart failure
7
32
21.9
17
53
32.1
22
63
34.9
13
59
22.0
59
207
28.5
1,709
13.1
18,047
13.9
1150
Cardiogenic shock
1
32
3.1
2
52
3.9
5
63
7.9
0
59
0.0
8
206
3.9
660
5.1
5,468
4.2
1151
Hypotension
3
32
9.4
1
53
1.9
2
63
3.2
1
59
1.7
7
207
3.4
690
5.3
6,096
4.7
1152
Tachycardia
7
32
21.9
13
53
24.5
21
63
33.3
10
59
17.0
51
207
24.6
2,552
19.6
26,581
20.5
1153
Cocaine use
68
0.7
1,100
1.1
1154
Cardiac arrest
1
31
3.2
0
53
0.0
3
63
4.8
0
59
0.0
4
206
1.9
613
4.7
5,325
4.1
1155
Pre-hospital
1
1
100.0
3
3
100.0
4
4
100.0
463
75.5
3,750
70.4
1156
Outside facility
0
1
0.0
0
3
0.0
0
4
0.0
106
17.3
1,160
21.8
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Acute and In-Hospital Medications and Dosing Errors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
%
199
97.5
11,883
98.3
118,736
98.4
204
96.6
12,405
97.7
123,935
97.7
111
203
54.7
6,652
53.6
67,297
54.2
0.0
0
207
0.0
5
0.0
77
0.1
58
19.0
31
206
15.1
2,012
15.9
19,776
15.8
55
98.2
158
182
86.8
9,533
85.1
98,930
85.7
3,952
44.6
40,109
43.2
691
7.5
7,000
7.2
1157
Acute and in-hospital
medications and dosing errors
1158
Any acute oral antiplatelet
28
30
93.3
51
52
98.1
59
60
98.3
56
57
98.3
194
1159
Aspirin
27
30
90.0
52
53
98.1
60
62
96.8
58
59
98.3
197
1160
Clopidogrel
21
32
65.6
30
52
57.7
28
61
45.9
32
58
55.2
1161
Ticlopidine
0
32
0.0
0
53
0.0
0
63
0.0
0
59
1162
Prasugrel
3
32
9.4
6
53
11.3
11
63
17.5
11
1163
Beta blocker
21
26
80.8
35
44
79.6
48
57
84.2
54
1164
ACE inhibitor
1165
Angiotensin receptor
blocker
1166
Aldosterone blocking agent
1167
Statin
1168
Non-statin lipid-lowering
agent
1169
GP IIb/IIIa inhibitor
1170
Eptifibatide
US Registry Pts
R4Q
Num
%
209
2.1
2,092
2.0
6,712
69.0
67,261
66.6
354
3.5
5,925
5.7
3
32
9.4
6
52
11.5
7
63
11.1
4
59
6.8
20
206
9.7
3,717
29.0
43,532
34.2
3
3
100.0
6
6
100.0
7
7
100.0
3
4
75.0
19
20
95.0
2,661
71.6
36,082
82.9
1,674
81.9
24,735
84.3
9.5
1171
Full dose
1172
Reduced dose
248
12.1
2,793
1173
Other
121
5.9
1,705
5.8
333
9.0
850
2.0
191
57.4
589
75.1
21
6.3
47
6.0
117
35.1
142
18.1
1174
Tirofiban
1175
Full dose
1176
Reduced dose
1177
Other
1178
3
0.0
0
6
0.0
0
7
0.0
0
4
0.0
0
20
0.0
0
3
0.0
0
6
0.0
0
7
0.0
1
4
25.0
1
20
5.0
715
19.2
6,532
15.0
1179
Any GP IIb-IIIa inhibitor
among PCI patients
3
18
16.7
5
35
14.3
7
35
20.0
4
39
10.3
19
127
15.0
3,397
41.3
38,297
48.3
1180
Started infusion pre-PCI (4)
0
3
0.0
0
5
0.0
1
7
14.3
0
4
0.0
1
19
5.3
335
9.9
5,750
15.0
1181
Started infusion peri-PCI (5)
3
3
100.0
5
5
100.0
6
7
85.7
4
4
100.0
18
19
94.7
3,049
89.8
32,394
84.6
29
32
90.6
49
52
94.2
55
62
88.7
57
58
98.3
190
204
93.1
11,860
92.2
119,823
93.4
1182
Abciximab
0
Anticoagulant
1183
IV unfractionated heparin
17
29
58.6
12
49
24.5
23
55
41.8
23
57
40.4
75
190
39.5
8,201
69.2
84,309
70.4
1184
LMWH
13
29
44.8
30
49
61.2
25
55
45.5
29
57
50.9
97
190
51.1
3,513
29.6
37,852
31.6
1185
Enoxaparin
13
29
44.8
30
49
61.2
25
55
45.5
29
57
50.9
97
190
51.1
3,156
26.6
36,538
30.5
220
9.3
2,570
8.7
1186
Initial IV bolus
1187
SubQ doses
1188
q 12 hours
909
38.2
11,949
40.1
1189
q 24 hours
585
24.6
8,333
28.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Acute and In-Hospital Medications and Dosing Errors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1190
Dalteparin
0
29
0.0
0
49
0.0
0
55
0.0
0
57
0.0
0
190
0.0
401
3.4
1,454
1191
Fondaparinux
0
29
0.0
0
49
0.0
0
55
0.0
0
57
0.0
0
190
0.0
34
0.3
509
0.4
1192
Direct thrombin inhibitors
15
29
51.7
31
49
63.3
33
55
60.0
37
57
64.9
116
190
61.1
4,311
36.4
39,357
32.9
1193
Bivalirudin
15
29
51.7
31
49
63.3
33
55
60.0
37
57
64.9
116
190
61.1
4,307
36.3
39,251
32.8
1194
Argatroban
0
29
0.0
0
49
0.0
0
55
0.0
0
57
0.0
0
190
0.0
7
0.1
119
0.1
1195
Lepirudin
0
29
0.0
0
49
0.0
0
55
0.0
0
57
0.0
0
190
0.0
2
0.0
25
0.0
1,000
49.9
11,373
48.1
1196
Dosing errors for
anticoagulants and GP IIbIIIa inhibitors
1197
Heparin, IV UFH-overall (all
AMI)
1.2
1198
Bolus
853
85.3
8,893
78.2
1199
Infusion
448
44.8
5,838
51.3
1200
Enoxaparin-overall
1201
Initial Dose > 1.05 mg/kg
192
14.7
1,901
11.5
1202
GP IIb-IIIa Inhibitor (All
AMI)
123
5.5
2,024
7.1
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
In-Hospital Procedures
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1203
In-hospital procedures
1204
Non-invasive stress test
1205
Diagnostic coronary
angiography
1206
Cath without prior noninvasive stress testing
1207
Diagnostic cath results
Num
Den
24
%
32
75.0
Num
Den
44
%
53
83.0
Num
Den
49
%
63
77.8
Num
Den
52
%
59
88.1
Num
Den
169
207
US Registry Pts
R4Q
%
Num
%
Num
%
476
4.7
4,997
4.8
81.6
11,202
86.0
111,393
85.7
8,510
97.0
86,724
96.3
1208
Non-obstructive CAD - all
vessels <50%
438
5.6
5,233
6.6
1209
Pt with no CAD (all native
vessels <=10% stenosis)
(w/o CABG)
259
3.3
2,891
3.7
1210
Diseased vessels
(including LM disease)
1211
LM disease (>=50%)
769
8.8
7,849
8.7
1212
LM and RCA disease (triple
vessel)
549
6.3
5,550
6.2
1213
LM w/out RCA disease
(double vessel)
220
2.5
2,299
2.6
1214
Diseased vessel w/or w/o
LM
1215
Single vessel disease
3,726
42.4
37,490
41.5
1216
Double vessel disease
2,439
27.8
25,478
28.2
1217
Triple vessel disease
1,980
22.5
19,626
21.7
1218
LV function
1219
Normal (EF >=50%)
15
32
46.9
27
53
50.9
29
63
46.0
34
59
57.6
105
207
50.7
7,430
57.0
68,510
52.7
1220
Mildly reduced (EF 40-49%)
10
32
31.3
13
53
24.5
15
63
23.8
19
59
32.2
57
207
27.5
2,408
18.5
25,320
19.5
1221
Moderately reduced (EF
25-39%)
5
32
15.6
7
53
13.2
10
63
15.9
4
59
6.8
26
207
12.6
1,753
13.4
20,200
15.5
1222
Severely reduced (EF <25%)
1
32
3.1
2
53
3.8
6
63
9.5
1
59
1.7
10
207
4.8
450
3.5
6,237
4.8
1223
Not Assessed
1
32
3.1
4
53
7.6
3
63
4.8
1
59
1.7
9
207
4.4
967
7.4
9,434
7.3
18
30
60.0
32
45
71.1
30
52
57.7
33
47
70.2
113
174
64.9
7,804
64.9
76,585
64.5
1224
Revascularization status
(6)
1225
PCI
1226
Stent type
1227
Bare metal stent
1228
Drug eluting stent
1229
1230
1231
5
15
33.3
4
30
13.3
11
29
37.9
11
33
33.3
31
107
29.0
2,086
28.9
22,362
31.5
10
15
66.7
26
30
86.7
18
29
62.1
22
33
66.7
76
107
71.0
5,171
71.7
48,809
68.8
Other
0
15
0.0
0
30
0.0
0
29
0.0
0
33
0.0
0
107
0.0
10
0.1
313
0.4
CABG
0
30
0.0
2
45
4.4
4
52
7.7
5
47
10.6
11
174
6.3
1,176
9.8
10,252
8.6
12
30
40.0
12
45
26.7
18
52
34.6
10
47
21.3
52
174
29.9
3,217
26.8
33,412
28.1
No revascularization
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Reperfusion Use
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1232
Reperfusion use
1233
Reperfusion candidates
1234
Transfers
1235
Non-transfers
Num
Den
9
9
%
9
9
100.0
100.0
Num
Den
11
11
%
11
11
100.0
100.0
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
24
26
92.3
30
30
100.0
74
76
97.4
4,491
85.8
42,483
84.1
3
3
100.0
5
5
100.0
8
8
100.0
1,188
87.0
13,116
84.6
21
23
91.3
25
25
100.0
66
68
97.1
3,303
85.4
29,367
83.9
1236
Reason contraindication to
reperfusion
1237
Primary reason for no
reperfusion
295
99.7
2,992
99.0
1238
Reason primary PCI not
performed
553
14.7
4,637
12.4
1239
Reason thrombolytics not
administered
3,185
84.5
31,060
83.1
1240
Reperfusion candidate, but
no PCI or thrombolytics
6
0.2
41
0.1
1241
Any thrombolytics
0
9
0.0
0
11
0.0
0
24
0.0
1
30
3.3
1
74
1.4
546
11.4
3,048
6.6
1242
D2B for non transfers <
=90 mins
5
7
71.4
10
11
90.9
20
20
100.0
24
25
96.0
59
63
93.7
2,798
94.5
25,075
94.6
2
50.0
4
75.0
6
66.7
36.9
2,554
1243
1244
Median time (minutes)
83.0
65.0
61.5
D2B for Transfers < = 90
mins
51.0
1
61.0
59.0
58.0
101.0
32.3
Median time (minutes)
<= 120 minutes
1
2
50.0
4
4
100.0
5
6
83.3
342
66.8
5,174
65.5
1247
Excluded from D2B non
transfer and D2B transfers
0
3
0.0
0
5
0.0
0
8
0.0
30
2.2
394
2.5
4
50.0
79
52.7
Door to needle
(thrombolytics) <= 30 min
1249
Median (minutes)
1250
Non-system reason for delay
1251
Door in door out transfer in
patients
1252
76.5
189
1246
1253
76.0
4
1245
1248
102.5
3
105.0
31.0
3
Median (minutes)
3
100.0
60.0
29.5
0
1
0.0
0
1
0.0
37
6.8
224
7.4
4
5
80.0
7
8
87.5
622
45.5
9,534
61.5
33.5
35.0
43.0
45.0
PCI Indications
1254
PCI for STEMI
9
18
50.0
11
35
31.4
23
35
65.7
30
39
76.9
73
127
57.5
4,592
55.6
43,781
54.6
1255
Immediate, primary PCI for
STEMI
9
9
100.0
11
11
100.0
23
23
100.0
30
30
100.0
73
73
100.0
3,975
86.6
39,967
91.3
1256
Rescue PCI
0
9
0.0
0
11
0.0
0
23
0.0
0
30
0.0
0
73
0.0
234
5.1
1,347
3.1
1257
1258
Median time (minutes)
Stable, successful reperfusion
for STEMI or completed
infarction post STEMI
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
226.0
0
9
0.0
0
11
0.0
0
23
Rev: 5
0.0
0
30
0.0
0
73
0.0
282
189.0
6.1
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
1,567
3.6
All Patients
Reperfusion Use
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1259
Other
0
9
0.0
0
11
0.0
0
23
0.0
0
30
0.0
0
73
0.0
101
2.2
900
2.1
1260
PCI for NSTEMI
9
18
50.0
24
35
68.6
12
35
34.3
9
39
23.1
54
127
42.5
3,651
44.2
36,191
45.2
1261
Thrombolytics and PCI based
on ECG
1262
Pre-hospital ECG to needle
1263
First medical contact to ECG
5.0
12.0
1264
ECG to arrival
40.0
17.0
1265
Arrival to needle
75.0
30.0
1266
Pre-hospital ECG to
balloon
1267
First medical contact to ECG
4.0
4.0
3.0
4.0
6.0
7.0
1268
ECG to arrival
17.0
24.0
21.0
21.0
21.0
22.0
Arrival to balloon
47.0
53.0
47.0
51.0
49.0
47.0
47.0
33.0
1269
1270
ECG after hospital arrival
to needle
1271
First medical contact to
arrival
1272
Arrival to ECG
-23.0
0.0
1273
ECG to needle
48.5
16.0
30.0
30.0
1274
ECG after hospital arrival
to balloon
1275
First medical contact to
arrival
1276
Arrival to ECG
0.0
0.0
1.5
0.0
2.0
2.0
1277
ECG to balloon
61.0
75.0
58.5
60.5
59.0
58.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
22.0
22.0
23.0
Rev: 5
22.0
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Early Invasive Management
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1278
Early invasive management
1279
Early catheterization
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1280
Within 48 hours
0
24
0.0
0
44
0.0
0
49
0.0
0
52
0.0
0
169
0.0
8,108
72.4
80,620
72.4
1281
Within 24 hours
0
24
0.0
0
44
0.0
0
49
0.0
0
52
0.0
0
169
0.0
7,248
64.7
69,671
62.6
1282
Early percutaneous
intervention (7)
1283
Within 48 hours
0
18
0.0
0
32
0.0
0
30
0.0
0
33
0.0
0
113
0.0
5,832
74.7
57,726
75.4
1284
Within 24 hours
0
18
0.0
0
32
0.0
0
30
0.0
0
33
0.0
0
113
0.0
5,370
68.8
51,966
67.9
3,546
46.0
31,965
41.9
379
4.9
4,926
6.5
1285
Acute antiplatelet therapy
among admissions with
early cath (8)
1286
P2Y12 only, %
1287
GP IIb-IIIa inhibitor only, %
1288
P2Y12 and GPI, %
2,375
30.8
26,558
34.8
Neither P2Y12 nor GPI, %
1,404
18.2
12,923
16.9
1289
1290
1291
Median time from hospital
presentation until…(hours)
Non-transfer in
1292
Diagnostic catheterization
1293
PCI
1294
CABG
1295
5.8
1.2
1.1
1.6
4.5
1.6
1.8
67.9
71.6
3.1
2.3
Transfer in
1296
Diagnostic catheterization
1297
PCI
1298
CABG
1299
2.3
2.3
0.4
0.3
0.4
2.0
1.3
62.4
64.6
2.5
3.5
Transfer and non-transfer
1300
Diagnostic catheterization
1301
PCI
1302
CABG
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
2.3
5.8
1.2
1.0
Rev: 5
1.4
1.7
1.7
65.2
68.5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Laboratory Results
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
1303
Laboratory results
1304
Positive cardiac markers
within first 24 hours
32
32
100.0
53
53
100.0
61
63
96.8
59
59
100.0
205
1305
Initial troponin
32
32
100.0
53
53
100.0
63
63
100.0
59
59
100.0
207
1306
Initial CK-MB
1307
Lipids
US Registry Pts
R4Q
%
Num
%
Num
%
207
99.0
12,812
98.3
126,831
97.5
207
100.0
12,884
98.8
128,588
98.8
5,812
57.3
78,648
75.1
21
32
65.6
36
53
67.9
36
63
57.1
40
59
67.8
133
207
64.3
10,244
78.6
104,433
80.3
76.8
1308
Drawn in hospital
0
21
0.0
0
36
0.0
0
36
0.0
0
40
0.0
0
133
0.0
7,634
74.5
80,180
1309
Drawn prior to admission
0
21
0.0
0
36
0.0
0
36
0.0
0
40
0.0
0
133
0.0
347
3.4
4,197
4.0
1310
HDL <40 mg/dL
4,597
57.4
48,338
57.4
1311
LDL <70 mg/dL
6
21
28.6
6
36
16.7
11
36
30.6
12
40
30.0
35
133
26.3
2,477
24.6
24,550
24.0
1312
LDL >= 70 to <= 100
8
21
38.1
16
36
44.4
13
36
36.1
13
40
32.5
50
133
37.6
3,163
31.5
31,747
31.0
1313
LDL >100 mg/dL
7
21
33.3
14
36
38.9
12
36
33.3
15
40
37.5
48
133
36.1
4,414
43.9
45,978
45.0
1314
Triglycerides >300 mg/dL
631
7.9
6,705
8.0
4,342
42.8
45,266
43.2
1315
BNP or NTproBNP collected
1316
Initial creatinine clearance
1317
>=60 cc/min
16
32
50.0
23
53
43.4
37
63
58.7
36
59
61.0
112
207
54.1
8,478
65.7
87,555
67.9
1318
30-59 cc/min
10
32
31.3
13
53
24.5
17
63
27.0
13
59
22.0
53
207
25.6
3,059
23.7
28,860
22.4
1319
<30 cc/min
6
32
18.8
15
53
28.3
9
63
14.3
10
59
17.0
40
207
19.3
1,241
9.6
11,387
8.8
1
32
3.1
4
53
7.6
0
63
0.0
2
59
3.4
7
207
3.4
269
2.1
3,136
2.4
1320
Initial hemoglobin < 9 g/dL
1321
Hemoglobin A1c
1322
Overall
3,746
37.0
42,068
40.2
1323
Among diabetes mellitus
1,610
52.2
18,507
53.9
1324
<7%
2,584
69.1
28,734
68.4
502
6.9
5,390
6.5
1325
INR>1.5
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
In-Hospital Events
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1326
Unadjusted death (9)
1327
Overall
1328
1329
1330
1331
1332
Num
Den
1
Lower 95% confidence limit
0.0
Upper 95% confidence limit
9.5
Excluding transfers in
1
%
31
3.2
Num
Den
6
%
51
11.8
2.9
3.2
6
Den
4
%
57
7.0
0.4
20.6
31
Num
11.8
Den
4
%
51
7.8
0.5
13.7
51
Num
52
7.7
3
Den
15
%
190
7.9
4.1
15.2
4
Num
6.7
14
%
645
5.1
4.8
11.7
45
Num
US Registry Pts
R4Q
7.8
520
%
5,642
4.7
5.7
4,077
Lower 95% confidence limit
0.0
2.9
0.5
0.0
3.9
5.2
4.6
Upper 95% confidence limit
9.5
20.6
14.9
14.0
11.8
6.1
4.9
1333
Risk adjusted Death (9)
1334
Overall
6.2
5.2
0.0
1335
Lower 95% confidence limit
4.0
4.3
0.0
1336
Upper 95% confidence limit
9.8
6.2
0.0
6.2
5.4
0.0
1337
Excluding transfers in
4.6
4.5
5.5
179
Num
1338
Lower 95% confidence limit
3.9
4.4
0.0
1339
Upper 95% confidence limit
10.0
6.5
0.0
4.8
1340
Clinical events
1341
Reinfarction
0
30
0.0
0
45
0.0
0
52
0.0
0
46
0.0
0
173
0.0
102
0.9
798
0.7
1342
Cardiogenic shock
0
30
0.0
1
45
2.2
2
52
3.9
0
47
0.0
3
174
1.7
430
3.6
3,344
2.8
1343
Heart failure
0
30
0.0
0
45
0.0
1
52
1.9
0
47
0.0
1
174
0.6
653
5.4
6,146
5.2
1344
CVA/stroke
0
30
0.0
0
45
0.0
0
52
0.0
1
47
2.1
1
174
0.6
72
0.6
649
0.6
0
1
0.0
0
1
0.0
11
15.3
71
11.0
1345
Hemorrhagic stroke
1346
Cardiac arrest
1
29
3.5
1
45
2.2
2
52
3.9
1
47
2.1
5
173
2.9
233
2.0
2,071
1.8
1347
Any of above events
1
30
3.3
2
45
4.4
4
52
7.7
2
47
4.3
9
174
5.2
1,179
9.8
10,653
9.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Bleeding Events
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1348
Unadjusted bleeding events (9)
1349
Overall
1350
1351
1352
1353
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
%
767
Lower 95% confidence limit
US Registry Pts
R4Q
8.0
7.5
Upper 95% confidence limit
559
%
8,010
8.4
8.3
5,562
Lower 95% confidence limit
7.6
8.0
1354
Upper 95% confidence limit
8.9
8.5
1355
Risk adjusted bleeding events
(9)
1356
Overall
8.6
0.0
1357
Lower 95% confidence limit
7.0
0.0
1358
Upper 95% confidence limit
10.5
0.0
8.4
0.0
1359
Excluding transfers in
1360
Lower 95% confidence limit
6.9
0.0
1361
Upper 95% confidence limit
10.4
0.0
1362
Bleeding events
1363
Suspected bleeding event
32
3.1
0
53
0.0
0
63
0.0
0
59
0.0
1
207
0.5
8.2
454
3.5
4,188
3.2
1364
Access site
72
19.9
862
26.1
1365
Retroperitoneal
30
8.3
234
7.1
1366
GI
96
26.5
1,173
35.5
1367
GU
1368
Other
1369
1
8.2
8.1
8.6
Excluding transfers in
Num
Surgical intervention required
19
5.3
180
5.4
155
42.8
972
29.4
65
18.1
654
19.9
1370
Suspected bleeding Event
among non-CABG patient
1
32
3.1
0
53
0.0
0
63
0.0
0
59
0.0
1
207
0.5
342
2.6
3,406
2.6
1371
RBC/whole blood
transfusion
5
32
15.6
7
53
13.2
7
63
11.1
4
59
6.8
23
207
11.1
1,327
10.2
12,306
9.5
83.4
1372
Initial hemoglobin >=9 g/dL
4
5
80.0
3
7
42.9
7
7
100.0
3
4
75.0
17
23
73.9
1,144
86.4
10,232
1373
Initial hemoglobin <9 g/dL
1
5
20.0
4
7
57.1
0
7
0.0
1
4
25.0
6
23
26.1
180
13.6
2,044
16.7
2,100
24.4
20,011
22.8
1374
Hemoglobin drop >=3 g/dL
1375
CABG related transfusion
0
32
0.0
0
53
0.0
0
63
0.0
0
59
0.0
0
207
0.0
427
3.3
4,074
3.1
1376
Non-CABG related
transfusion
0
32
0.0
0
53
0.0
0
63
0.0
0
59
0.0
0
207
0.0
542
4.2
5,889
4.5
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Discharge Therapies
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
1377
Discharge therapies
1378
Medications
1379
Any oral antiplatelet
29
29
100.0
43
43
100.0
47
49
95.9
46
46
100.0
165
1380
Aspirin
27
28
96.4
40
40
100.0
41
41
100.0
43
43
100.0
151
1381
P2Y12
US Registry Pts
R4Q
%
Num
%
Num
%
167
98.8
11,242
98.1
112,520
98.1
152
99.3
10,231
98.7
102,172
98.4
61.7
1382
Clopidogrel
25
29
86.2
29
42
69.1
25
48
52.1
24
45
53.3
103
164
62.8
6,948
62.8
67,642
1383
Ticlopidine
0
29
0.0
0
41
0.0
0
49
0.0
1
45
2.2
1
164
0.6
8
0.1
146
0.1
1384
Prasugrel
1
29
3.5
6
42
14.3
11
49
22.5
12
46
26.1
30
166
18.1
1,973
17.6
22,173
20.0
1385
Among medically managed
patients (excl d/c on Warfarin)
8
11
72.7
6
11
54.6
7
15
46.7
5
7
71.4
26
44
59.1
1,295
51.6
14,474
55.6
1386
Among PCI patients (excl d/c
on Warfarin)
18
18
100.0
27
28
96.4
26
26
100.0
31
32
96.9
102
104
98.1
6,869
97.3
67,583
96.8
1387
Among CABG patients (excl
d/c on Warfarin)
0
2
0.0
0
3
0.0
0
5
0.0
0
10
0.0
303
30.2
3,286
38.2
1388
Warfarin
0
29
0.0
0
40
0.0
5
49
10.2
3
46
6.5
8
164
4.9
844
7.4
8,783
7.8
1389
Beta blocker
27
28
96.4
39
39
100.0
44
44
100.0
44
44
100.0
154
155
99.4
10,404
97.3
105,866
97.1
1390
ACE inhibitor
19
27
70.4
25
39
64.1
33
43
76.7
37
42
88.1
114
151
75.5
6,715
66.2
67,829
65.6
1391
Angiotensin receptor
blocker
0
27
0.0
6
40
15.0
3
46
6.5
0
45
0.0
9
158
5.7
1,224
11.7
11,556
10.9
1392
ACE/ARB overall
19
27
70.4
31
41
75.6
34
46
73.9
37
45
82.2
121
159
76.1
7,866
74.7
78,447
73.4
1393
ACE/ARB among ideal
patients
3
3
100.0
6
7
85.7
7
9
77.8
1
1
100.0
17
20
85.0
1,333
90.2
16,835
89.3
1394
Aldosterone blocking agent
1395
Statin
1396
Non-statin lipid-lowering
agent
1397
Discharge recommendation
1398
Smoking counseling (among
smokers)
1399
Dietary modification
counseling
1400
Exercise counseling
27
29
93.1
43
43
100.0
49
49
100.0
46
46
100.0
165
167
1401
Cardiac rehab referral
11
29
37.9
28
43
65.1
29
44
65.9
38
42
90.5
106
158
1402
0
29
0.0
0
39
0.0
0
49
0.0
0
46
0.0
0
163
0.0
533
4.7
4,912
4.3
28
28
100.0
39
39
100.0
48
48
100.0
45
45
100.0
160
160
100.0
10,529
98.9
105,094
98.6
0
1
0.0
0
1
0.0
756
7.7
11,020
10.8
11
11
100.0
52
52
100.0
3,311
98.2
40,868
98.5
8,543
95.6
88,093
95.7
98.8
9,839
87.4
93,009
84.0
67.1
7,022
69.7
80,063
77.8
8
8
100.0
17
17
100.0
16
16
100.0
Discharge location
1403
Home
26
31
83.9
40
47
85.1
42
58
72.4
44
55
80.0
152
191
79.6
10,686
86.3
106,122
85.4
1404
Extended care/transitional
care unit
0
31
0.0
0
47
0.0
0
58
0.0
0
55
0.0
0
191
0.0
522
4.2
5,141
4.1
1405
Other hospital
1
31
3.2
2
47
4.3
6
58
10.3
8
55
14.6
17
191
8.9
360
2.9
5,533
4.5
1406
Nursing home
3
31
9.7
4
47
8.5
9
58
15.5
2
55
3.6
18
191
9.4
486
3.9
4,545
3.7
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Discharge Therapies
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1407
Hospice
0
31
0.0
0
47
0.0
0
58
0.0
0
55
0.0
0
191
0.0
169
1.4
1,473
1.2
1408
Other
0
31
0.0
0
47
0.0
0
58
0.0
0
55
0.0
0
191
0.0
54
0.4
628
0.5
1409
Left against medical advice
(AMA)
1
31
3.2
1
47
2.1
1
58
1.7
1
55
1.8
4
191
2.1
109
0.9
876
0.7
31
32
96.9
47
53
88.7
59
63
93.7
55
59
93.2
192
207
92.8
12,389
95.0
124,338
95.6
1
32
3.1
6
53
11.3
4
63
6.4
4
59
6.8
15
207
7.3
651
5.0
5,786
4.5
0
32
0.0
2
53
3.8
4
63
6.4
3
59
5.1
9
207
4.4
646
5.0
4,659
3.6
1410
Discharge status
1411
Alive
1412
Deceased
1413
Comfort measures only
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
All Patients
Length of stay
Sample Hospital
2011Q3
2011Q4
2012Q1
2012Q2
My Hospital R4Q
Line#
Description
1414
Length of stay (days)
1415
Total length of stay-all
patients
1416
Overall median
1417
Early catheterization median
1418
Any PCI median
1419
Any CABG median
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Num
3.0
3.0
Den
%
Num
3.0
Den
%
Num
Den
2.0
%
Num
2.0
Den
%
Num
3.0
Den
%
US
Comparison
Group Pts
R4Q
Num
US Registry Pts
R4Q
%
Num
%
3.0
3.0
3.0
3.0
3.0
2.0
2.0
2.0
3.0
3.0
15.5
9.0
10.5
10.0
9.0
9.0
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Demographics and Payors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1420
Demographics
1421
Sex
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1422
Male
6
9
66.7
7
11
63.6
20
26
76.9
23
30
76.7
56
76
73.7
3,782
72.1
35,689
70.5
1423
Female
3
9
33.3
4
11
36.4
6
26
23.1
7
30
23.3
20
76
26.3
1,463
27.9
14,915
29.5
1424
Age at admission
1425
Mean age
65
59
60
60
60
63
1426
Median age
67
54
59
61
59
62
1427
18-44
0
9
0.0
0
11
0.0
2
26
7.7
2
30
6.7
4
76
5.3
354
6.8
4,484
8.9
1428
45-54
2
9
22.2
6
11
54.6
7
26
26.9
8
30
26.7
23
76
30.3
1,030
19.6
11,488
22.7
1429
55-64
1
9
11.1
3
11
27.3
11
26
42.3
12
30
40.0
27
76
35.5
1,652
31.5
15,158
30.0
1430
65-69
2
9
22.2
0
11
0.0
2
26
7.7
5
30
16.7
9
76
11.8
634
12.1
5,957
11.8
1431
70-74
2
9
22.2
0
11
0.0
0
26
0.0
1
30
3.3
3
76
4.0
501
9.6
4,406
8.7
1432
75-79
1
9
11.1
1
11
9.1
2
26
7.7
1
30
3.3
5
76
6.6
408
7.8
3,517
7.0
1433
>= 80
1
9
11.1
1
11
9.1
2
26
7.7
1
30
3.3
5
76
6.6
666
12.7
5,594
11.1
Medicare age ( >= 65)
6
9
66.7
2
11
18.2
6
26
23.1
8
30
26.7
22
76
29.0
2,209
42.1
19,474
38.5
1434
1435
62
61
Race
1436
White
9
9
100.0
10
11
90.9
20
26
76.9
19
30
63.3
58
76
76.3
4,610
87.9
43,696
86.4
1437
Black/African American
0
9
0.0
0
11
0.0
3
26
11.5
9
30
30.0
12
76
15.8
175
3.3
5,167
10.2
1438
Asian
0
9
0.0
0
11
0.0
2
26
7.7
2
30
6.7
4
76
5.3
274
5.2
1,083
2.1
1439
American Indian/Alaskan
0
9
0.0
0
11
0.0
1
26
3.9
0
30
0.0
1
76
1.3
49
0.9
290
0.6
1440
Hawaiian/Pacific Islander
0
9
0.0
1
11
9.1
0
26
0.0
0
30
0.0
1
76
1.3
40
0.8
91
0.2
2
9
22.2
3
11
27.3
3
26
11.5
2
30
6.7
10
76
13.2
592
11.4
2,512
5.0
1441
Hispanic or Latino Ethnicity
1442
Insurance payors
1443
Private
5
9
55.6
6
11
54.6
15
26
57.7
13
30
43.3
39
76
51.3
2,920
55.7
28,160
55.7
1444
Medicare
5
9
55.6
3
11
27.3
10
26
38.5
13
30
43.3
31
76
40.8
2,052
39.1
19,960
39.4
1445
Medicaid
2
9
22.2
2
11
18.2
3
26
11.5
5
30
16.7
12
76
15.8
436
8.3
4,123
8.2
1446
Military
0
9
0.0
1
11
9.1
0
26
0.0
3
30
10.0
4
76
5.3
229
4.4
1,436
2.8
1447
State-specific (non-Medicaid)
0
9
0.0
0
11
0.0
1
26
3.9
1
30
3.3
2
76
2.6
174
3.3
616
1.2
1448
Indian Health Service
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
6
0.1
85
0.2
1449
Non-U.S Insurance
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
9
0.2
72
0.1
1450
None
0
9
0.0
1
11
9.1
3
26
11.5
5
30
16.7
9
76
11.8
722
13.8
8,248
16.3
1451
Transfers in
0
9
0.0
0
11
0.0
3
26
11.5
5
30
16.7
8
76
10.5
1,367
26.1
15,524
30.7
1452
Not transferred in
9
9
100.0
11
11
100.0
23
26
88.5
25
30
83.3
68
76
89.5
3,878
73.9
35,080
69.3
1453
Transfers out
0
9
0.0
0
11
0.0
3
26
11.5
5
30
16.7
8
76
10.5
190
3.6
1,785
3.5
1454
Not transferred out
9
9
100.0
10
11
90.9
20
26
76.9
25
30
83.3
64
76
84.2
4,707
89.7
45,783
90.5
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Medical History/Home Medications
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
1455
History and risk factors
1456
Current smoker (< 1 year)
5
9
55.6
2
11
18.2
12
26
46.2
11
30
36.7
30
76
39.5
1457
Hypertension
8
9
88.9
7
11
63.6
18
26
69.2
26
30
86.7
59
76
77.6
1458
Dyslipidemia
1459
Currently on dialysis
1460
Chronic lung disease
1461
Diabetes mellitus
1462
Diabetes therapy:
1
9
11.1
0
11
0.0
0
26
0.0
0
30
0.0
1
76
1.3
Num
US Registry Pts
R4Q
%
Num
%
1,836
35.0
21,477
42.5
3,323
63.4
33,112
65.5
2,179
53.6
21,363
52.8
55
1.1
502
1.0
328
8.1
4,007
9.9
4
9
44.4
1
10
10.0
7
26
26.9
14
30
46.7
26
75
34.7
1,269
24.2
12,646
25.0
8.3
1463
None
0
4
0.0
0
1
0.0
0
7
0.0
0
14
0.0
0
26
0.0
103
8.1
1,044
1464
Diet
0
4
0.0
0
1
0.0
0
7
0.0
0
14
0.0
0
26
0.0
91
7.2
733
5.8
1465
Oral
0
4
0.0
0
1
0.0
0
7
0.0
0
14
0.0
0
26
0.0
462
36.4
5,255
41.6
1466
Insulin
0
4
0.0
0
1
0.0
0
7
0.0
0
14
0.0
0
26
0.0
255
20.1
2,917
23.1
1467
Other
0
4
0.0
0
1
0.0
0
7
0.0
0
14
0.0
0
26
0.0
13
1.0
61
0.5
1,442
35.8
15,554
38.8
18.8
1468
Obesity (BMI >= 30)
1469
Prior MI
718
17.7
7,608
1470
Prior heart failure
192
4.7
2,071
5.1
1471
Prior PCI
770
18.9
8,200
20.3
1472
Prior CABG
227
5.6
2,617
6.5
1473
Atrial fibrillation or flutter
(past 2 weeks)
197
4.8
1,874
4.6
1474
Cerebrovascular disease
7.5
1475
Prior stroke
1476
Peripheral arterial disease
0
9
0.0
0
11
0.0
3
26
11.5
0
30
0.0
3
76
4.0
337
6.4
3,771
0
9
0.0
0
11
0.0
3
26
11.5
0
30
0.0
3
76
4.0
230
4.4
2,551
5.1
2
9
22.2
0
11
0.0
2
26
7.7
0
29
0.0
4
75
5.3
221
4.2
2,817
5.6
1477
Home medications
1478
Aspirin
1,263
31.0
13,174
32.6
1479
Clopidogrel
252
6.2
3,310
8.2
1480
Ticlopidine
0
0.0
27
0.1
1481
Prasugrel
31
0.8
416
1.0
1482
Warfarin
116
2.9
1,116
2.8
1483
Beta blocker
955
23.5
10,969
27.1
1484
ACE inhibitor
855
21.0
9,410
23.3
1485
Angiotensin receptor
blocker
310
7.6
3,188
7.9
1486
Aldosterone blocking agent
1487
Statin
1488
Non-statin lipid-lowering
agent
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
44
1.1
557
1.4
1,255
30.8
12,503
30.9
213
5.2
2,671
6.6
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Hospital Presentation
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1489
Hospital presentation
1490
Means of transport (first
facility)
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1491
Self/family
7
9
77.8
5
11
45.5
9
26
34.6
9
30
30.0
30
76
39.5
2,349
44.8
24,384
48.2
1492
Ambulance
2
9
22.2
6
11
54.6
17
26
65.4
21
30
70.0
46
76
60.5
2,810
53.6
25,252
49.9
1493
Mobile ICU
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
3
0.1
284
0.6
1494
Air
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
81
1.5
643
1.3
58.6
1495
Means of fransfer (Outside
Facility)
1496
Ambulance
3
3
100.0
5
5
100.0
8
8
100.0
678
49.7
9,085
1497
Mobile ICU
0
3
0.0
0
5
0.0
0
8
0.0
50
3.7
687
4.4
1498
Air
0
3
0.0
0
5
0.0
0
8
0.0
635
46.6
5,725
36.9
3,096
76.1
28,060
69.4
1499
1500
1501
Location of first evaluation
ED
Median hours from arrival to
transfer from ED
0.6
0.6
1502
Cath lab
683
16.8
10,274
25.4
1503
Other
290
7.1
2,126
5.3
1504
First ECG obtained
1505
Pre hospital (3)
1
9
11.1
6
11
54.6
16
23
69.6
17
25
68.0
40
68
58.8
1,783
46.0
14,785
42.2
1506
After 1st hospital arrival
8
9
88.9
5
11
45.5
7
23
30.4
8
25
32.0
28
68
41.2
2,094
54.0
20,266
57.8
1507
Median time to 1st ECG
4.5
1508
ECG less than or equal to 10
min of presentation
1509
5.0
4.0
3.5
4.0
6.0
6.0
8
8
100.0
4
5
80.0
7
7
100.0
8
8
100.0
27
28
96.4
1,578
76.1
15,140
74.7
STEMI ECG findings
1510
ST elevation
9
9
100.0
11
11
100.0
26
26
100.0
30
30
100.0
76
76
100.0
5,079
97.0
49,014
96.9
1511
LBBB
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
132
2.5
1,118
2.2
1512
Isolated posterior MI
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
27
0.5
430
0.9
1513
STEMI first noted
1514
First ECG
6
9
66.7
8
11
72.7
25
26
96.2
26
30
86.7
65
76
85.5
4,607
88.0
43,914
86.9
1515
Subsequent ECG
3
9
33.3
3
11
27.3
1
26
3.9
4
30
13.3
11
76
14.5
626
12.0
6,624
13.1
1516
Median time from symptom
onset to presentation
(hours) (2)
1.4
2.1
1.2
1.0
1.2
1.6
1.6
1517
>= 6 hours
1
9
11.1
3
11
27.3
4
23
17.4
3
25
12.0
11
68
16.2
492
13.6
3,988
12.5
1518
< 6 hours
8
9
88.9
8
11
72.7
19
23
82.6
22
25
88.0
57
68
83.8
3,067
84.5
27,044
84.6
1519
Cardiac status on first medical
contact
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Hospital Presentation
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1520
Heart failure
0
9
0.0
1
11
9.1
7
26
26.9
2
30
6.7
10
76
13.2
384
7.3
3,801
7.5
1521
Cardiogenic shock
0
9
0.0
1
11
9.1
3
26
11.5
0
30
0.0
4
76
5.3
468
8.9
3,991
7.9
1522
Hypotension
1
9
11.1
0
11
0.0
1
26
3.9
0
30
0.0
2
76
2.6
430
8.2
3,674
7.3
1523
Tachycardia
0
9
0.0
0
11
0.0
8
26
30.8
4
30
13.3
12
76
15.8
850
16.3
8,409
16.7
1524
Cocaine use
32
0.8
500
1.2
1525
Cardiac arrest
0
8
0.0
0
11
0.0
1
26
3.9
0
30
0.0
1
75
1.3
441
8.5
3,946
7.9
1526
Pre-hospital
1
1
100.0
1
1
100.0
336
76.2
2,725
69.1
1527
Outside facility
0
1
0.0
0
1
0.0
76
17.2
912
23.1
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Acute and In-Hospital Medications and Dosing Errors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
%
Num
%
4,888
99.0
47,061
99.1
5,075
98.6
48,899
98.4
68.9
3,299
65.5
31,242
64.3
76
0.0
2
0.0
29
0.1
24
76
31.6
1,278
25.2
13,046
26.7
64
68
94.1
3,866
87.3
38,310
87.2
1,840
51.9
17,702
50.1
183
4.9
1,755
4.7
1528
Acute and in-hospital
medications and dosing errors
1529
Any acute oral antiplatelet
9
9
100.0
11
11
100.0
24
25
96.0
29
29
100.0
73
74
98.7
1530
Aspirin
9
9
100.0
11
11
100.0
25
26
96.2
30
30
100.0
75
76
98.7
1531
Clopidogrel
8
9
88.9
8
11
72.7
14
25
56.0
21
29
72.4
51
74
1532
Ticlopidine
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
1533
Prasugrel
2
9
22.2
3
11
27.3
10
26
38.5
9
30
30.0
1534
Beta blocker
7
7
100.0
9
10
90.0
21
24
87.5
27
27
100.0
1535
ACE inhibitor
1536
Angiotensin receptor
Blocker
1537
Aldosterone blocking agent
1538
Statin
1539
Non-statin lipid-lowering
agent
1540
GP IIb/IIIa inhibitor
1541
Eptifibatide
Num
US Registry Pts
R4Q
79
2.0
677
1.7
2,999
75.9
28,502
72.7
82
2.0
1,574
3.9
3
9
33.3
3
11
27.3
6
26
23.1
3
30
10.0
15
76
19.7
2,253
43.4
25,609
51.3
3
3
100.0
3
3
100.0
6
6
100.0
2
3
66.7
14
15
93.3
1,495
66.4
19,833
77.5
1542
Full dose
916
83.7
13,283
84.5
1543
Reduced dose
122
11.1
1,385
8.8
1544
Other
57
5.2
993
6.3
168
7.5
417
1.6
94
56.0
266
71.1
6
3.6
20
5.4
67
39.9
86
23.0
1545
Tirofiban
1546
Full dose
1547
Reduced dose
1548
Other
1549
3
0.0
0
3
0.0
0
6
0.0
0
3
0.0
0
15
0.0
0
3
0.0
0
3
0.0
0
6
0.0
1
3
33.3
1
15
6.7
588
26.1
5,326
20.8
1550
Any GP IIb-IIIa inhibitor
among PCI patients
3
9
33.3
3
11
27.3
6
23
26.1
3
30
10.0
15
73
20.6
2,185
48.6
24,497
57.1
1551
Started infusion pre-PCI (4)
0
3
0.0
0
3
0.0
0
6
0.0
0
3
0.0
0
15
0.0
65
3.0
1,270
5.2
1552
Started infusion peri-PCI (5)
3
3
100.0
3
3
100.0
6
6
100.0
3
3
100.0
15
15
100.0
2,116
96.8
23,138
94.5
1553
Abciximab
0
9
9
100.0
11
11
100.0
24
26
92.3
30
30
100.0
74
76
97.4
5,001
96.0
48,033
95.5
1554
Anticoagulant
IV unfractionated heparin
8
9
88.9
4
11
36.4
12
24
50.0
7
30
23.3
31
74
41.9
3,789
75.8
36,943
76.9
1555
LMWH
2
9
22.2
1
11
9.1
4
24
16.7
6
30
20.0
13
74
17.6
651
13.0
7,486
15.6
1556
Enoxaparin
2
9
22.2
1
11
9.1
4
24
16.7
6
30
20.0
13
74
17.6
572
11.4
7,155
14.9
54
12.4
1,070
18.1
1557
Initial IV bolus
1558
SubQ doses
1559
q 12 hours
147
33.6
1,523
25.7
1560
q 24 hours
152
34.8
2,654
44.8
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Acute and In-Hospital Medications and Dosing Errors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1561
Dalteparin
0
9
0.0
0
11
0.0
0
24
0.0
0
30
0.0
0
74
0.0
82
1.6
348
1562
Fondaparinux
0
9
0.0
0
11
0.0
0
24
0.0
0
30
0.0
0
74
0.0
8
0.2
133
0.3
1563
Direct thrombin inhibitors
8
9
88.9
11
11
100.0
22
24
91.7
30
30
100.0
71
74
96.0
2,208
44.2
19,737
41.1
1564
Bivalirudin
8
9
88.9
11
11
100.0
22
24
91.7
30
30
100.0
71
74
96.0
2,208
44.2
19,692
41.0
1565
Argatroban
0
9
0.0
0
11
0.0
0
24
0.0
0
30
0.0
0
74
0.0
0
0.0
51
0.1
1566
Lepirudin
0
9
0.0
0
11
0.0
0
24
0.0
0
30
0.0
0
74
0.0
0
0.0
14
0.0
64
47.8
782
47.7
1567
Dosing errors for
anticoagulants and GP IIbIIIa inhibitors
1568
Heparin, IV UFH-overall (All
AMI)
0.7
1569
Bolus
52
81.3
671
85.8
1570
Infusion
20
31.3
250
32.0
1571
Enoxaparin-overall
1572
Initial Dose > 1.05 mg/kg
14
21.2
136
12.2
1573
GP IIb-IIIa inhibitor (all
AMI)
76
6.0
1,191
7.3
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
In-Hospital Procedures
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1574
In-hospital procedures
1575
Non-invasive stress test
1576
Diagnostic coronary
angiography
1577
Cath without prior noninvasive stress testing
1578
Diagnostic cath results
Num
Den
9
%
9
100.0
Num
Den
11
%
11
100.0
Num
Den
26
%
26
100.0
Num
Den
30
%
30
100.0
Num
Den
76
%
76
100.0
Num
US Registry Pts
R4Q
%
Num
%
89
2.2
1,188
2.9
5,052
96.4
48,398
95.7
3,847
97.8
37,697
97.1
1579
Non-obstructive CAD - all
vessels <50%
89
2.4
1,084
3.0
1580
Pt with no CAD (all native
vessels <=10% stenosis)
(w/o CABG)
55
1.5
659
1.8
1581
Diseased vessels
(including LM disease)
1582
LM disease (>=50%)
249
6.3
2,241
5.8
1583
LM and RCA disease (triple
vessel)
180
4.6
1,628
4.2
1584
LM w/out RCA disease
(double vessel)
69
1.8
613
1.6
1585
Diseased vessel w/or w/o
LM
1586
Single vessel disease
1,995
50.7
19,343
49.8
1587
Double vessel disease
1,095
27.8
11,157
28.7
1588
Triple vessel disease
707
18.0
6,812
17.5
1589
LV function
1590
Normal (EF >=50%)
3
9
33.3
5
11
45.5
13
26
50.0
18
30
60.0
39
76
51.3
2,873
54.8
24,713
48.8
1591
Mildly reduced (EF 40-49%)
6
9
66.7
4
11
36.4
6
26
23.1
10
30
33.3
26
76
34.2
1,123
21.4
11,602
22.9
1592
Moderately reduced (EF
25-39%)
0
9
0.0
2
11
18.2
4
26
15.4
1
30
3.3
7
76
9.2
799
15.2
8,951
17.7
1593
Severely reduced (EF <25%)
0
9
0.0
0
11
0.0
1
26
3.9
1
30
3.3
2
76
2.6
164
3.1
2,239
4.4
1594
Not Assessed
0
9
0.0
0
11
0.0
2
26
7.7
0
30
0.0
2
76
2.6
271
5.2
2,955
5.8
9
9
100.0
10
10
100.0
20
20
100.0
25
25
100.0
64
64
100.0
4,153
88.3
40,491
88.5
1595
Revascularization status
(6)
1596
PCI
1597
Stent type
1598
Bare metal stent
3
9
33.3
2
9
22.2
6
20
30.0
8
25
32.0
19
63
30.2
1,267
33.3
13,647
36.6
1599
Drug eluting stent
6
9
66.7
7
9
77.8
14
20
70.0
17
25
68.0
44
63
69.8
2,562
67.3
23,749
63.7
1600
Other
0
9
0.0
0
9
0.0
0
20
0.0
0
25
0.0
0
63
0.0
7
0.2
163
0.4
1601
CABG
0
9
0.0
0
10
0.0
0
20
0.0
1
25
4.0
1
64
1.6
292
6.2
2,573
5.6
0
9
0.0
0
10
0.0
0
20
0.0
0
25
0.0
0
64
0.0
384
8.2
3,817
8.3
1602
No revascularization
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Reperfusion Use
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1603
Reperfusion use
1604
Reperfusion candidates
1605
Transfers
1606
Non-transfers
Num
Den
9
9
%
9
9
100.0
100.0
Num
Den
11
11
%
11
11
100.0
100.0
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
24
26
92.3
30
30
100.0
74
76
97.4
4,491
85.8
42,483
84.1
3
3
100.0
5
5
100.0
8
8
100.0
1,188
87.0
13,116
84.6
21
23
91.3
25
25
100.0
66
68
97.1
3,303
85.4
29,367
83.9
1607
Reason contraindication to
reperfusion
1608
Primary reason for no
reperfusion
295
99.7
2,992
99.0
1609
Reason primary PCI not
performed
553
14.7
4,637
12.4
1610
Reason thrombolytics not
administered
3,185
84.5
31,060
83.1
1611
Reperfusion candidate, but
no PCI or thrombolytics
6
0.2
41
0.1
1612
Any thrombolytics
0
9
0.0
0
11
0.0
0
24
0.0
1
30
3.3
1
74
1.4
546
11.4
3,048
6.6
1613
D2B for non transfers <=
90 minutes
5
7
71.4
10
11
90.9
20
20
100.0
24
25
96.0
59
63
93.7
2,798
94.5
25,075
94.6
2
50.0
4
75.0
6
66.7
36.9
2,554
1614
1615
Median time (minutes)
83.0
65.0
61.5
D2B for Transfers <= 90
minutes
51.0
1
61.0
59.0
76.5
189
58.0
101.0
32.3
Median time (minutes)
1617
<= 120 minutes
1
2
50.0
4
4
100.0
5
6
83.3
342
66.8
5,174
65.5
1618
Excluded from D2B non
transfer and D2B transfers
0
3
0.0
0
5
0.0
0
8
0.0
30
2.2
394
2.5
4
50.0
79
52.7
Door to needle
(Thrombolytics) <=30 min
1620
Median (minutes)
1621
Non-system reason for delay
1622
Door in door out transfer in
patients
1623
76.0
4
1616
1619
102.5
3
105.0
31.0
3
Median (minutes)
3
100.0
60.0
29.5
0
1
0.0
0
1
0.0
37
6.8
224
7.4
4
5
80.0
7
8
87.5
622
45.5
9,534
61.5
33.5
35.0
43.0
45.0
1624
PCI indications
1625
PCI for STEMI
9
9
100.0
11
11
100.0
23
23
100.0
30
30
100.0
73
73
100.0
4,466
98.8
42,766
98.8
1626
Immediate, primary PCI for
STEMI
9
9
100.0
11
11
100.0
23
23
100.0
30
30
100.0
73
73
100.0
3,925
87.9
39,561
92.5
1627
Rescue PCI
0
9
0.0
0
11
0.0
0
23
0.0
0
30
0.0
0
73
0.0
230
5.2
1,318
3.1
1628
Median time (minutes)
1629
Stable, successful reperfusion
for STEMI or completed
infarction post STEMI
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
226.0
0
9
0.0
0
11
0.0
0
23
Rev: 5
0.0
0
30
0.0
0
73
0.0
264
189.0
5.9
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
1,454
3.4
STEMI Patients
Reperfusion Use
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
1630
1631
Description
Other
Num
Den
0
%
9
0.0
Num
Den
0
%
11
0.0
Num
Den
0
%
23
0.0
Num
Den
0
%
30
0.0
Num
Den
0
%
73
0.0
Num
US Registry Pts
R4Q
%
47
1.1
Num
%
433
Thrombolytics and PCI based
on ECG
1632
Pre-hospital ECG to needle
1633
First medical contact to ECG
5.0
12.0
1634
ECG to arrival
40.0
17.0
1635
Arrival to needle
75.0
30.0
1636
Pre-hospital ECG to
balloon
1637
First medical contact to ECG
4.0
4.0
3.0
4.0
6.0
7.0
1638
ECG to arrival
17.0
24.0
21.0
21.0
21.0
22.0
Arrival to balloon
47.0
53.0
47.0
51.0
49.0
47.0
47.0
33.0
1639
1640
ECG after hospital arrival
to needle
1641
First medical contact to
arrival
1642
Arrival to ECG
-23.0
0.0
1643
ECG to needle
48.5
16.0
30.0
30.0
1644
ECG after hospital arrival
to balloon
1645
First medical contact to
arrival
1646
Arrival to ECG
0.0
0.0
1.5
0.0
2.0
2.0
1647
ECG to balloon
61.0
75.0
58.5
60.5
59.0
58.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
22.0
22.0
23.0
Rev: 5
22.0
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
1.0
STEMI Patients
Early Invasive Management
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1648
Early invasive management
1649
Early catheterization
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1650
Within 48 hours
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
3,786
74.9
37,996
78.5
1651
Within 24 hours
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
3,739
74.0
37,613
77.7
1652
Early percutaneous
intervention (7)
1653
Within 48 hours
0
9
0.0
0
10
0.0
0
20
0.0
0
25
0.0
0
64
0.0
3,157
76.0
32,081
79.2
1654
Within 24 hours
0
9
0.0
0
10
0.0
0
20
0.0
0
25
0.0
0
64
0.0
3,129
75.3
31,846
78.7
1,705
47.3
14,840
41.2
83
2.3
1,295
3.6
1,582
43.9
17,789
49.4
234
6.5
2,120
5.9
1655
Acute antiplatelet therapy
among admissions with
early cath (8)
1656
P2Y12 only, %
1657
GP IIb-IIIa inhibitor only, %
1658
P2Y12 and GPI, %
1659
1660
Neither P2Y12 nor GPI, %
Median time from hospital
presentation Until…(hours)
1661
Non-transfer in
1662
Diagnostic catheterization
1663
PCI
1664
CABG
1665
Transfer in
1666
Diagnostic catheterization
1667
PCI
1668
CABG
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
0.8
1.6
1.1
1.0
0.9
0.4
0.3
Rev: 5
1.1
0.3
0.8
1.1
1.1
26.4
33.6
0.4
0.3
0.7
0.5
44.1
45.1
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Laboratory Results
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
1669
Laboratory results
1670
Positive cardiac markers
within first 24 hours
9
9
100.0
11
11
100.0
24
26
92.3
30
30
100.0
74
76
97.4
1671
Initial troponin
9
9
100.0
11
11
100.0
26
26
100.0
30
30
100.0
76
76
100.0
1672
Initial CK-MB
1673
Lipids
Num
US Registry Pts
R4Q
%
Num
%
5,017
95.7
47,311
93.5
5,116
97.5
49,254
97.3
2,531
62.2
30,862
76.3
8
9
88.9
9
11
81.8
18
26
69.2
23
30
76.7
58
76
76.3
4,313
82.3
41,964
83.0
78.0
1674
Drawn in hospital
0
8
0.0
0
9
0.0
0
18
0.0
0
23
0.0
0
58
0.0
3,258
75.5
32,712
1675
Drawn prior to admission
0
8
0.0
0
9
0.0
0
18
0.0
0
23
0.0
0
58
0.0
102
2.4
963
2.3
1676
HDL <40 mg/dL
1,983
58.8
20,215
60.0
1677
LDL <70 mg/dL
2
8
25.0
1
9
11.1
5
18
27.8
6
23
26.1
14
58
24.1
919
21.7
8,360
20.3
1678
LDL >= 70 to <= 100
2
8
25.0
4
9
44.4
8
18
44.4
8
23
34.8
22
58
37.9
1,290
30.5
12,573
30.6
1679
LDL >100 mg/dL
4
8
50.0
4
9
44.4
5
18
27.8
9
23
39.1
22
58
37.9
2,023
47.8
20,198
49.1
1680
Triglycerides >300 mg/dL
255
7.6
2,645
7.9
1,491
36.6
13,895
34.3
1681
BNP or NTproBNP collected
1682
Initial creatinine clearance
1683
>=60 cc/min
5
9
55.6
9
11
81.8
21
26
80.8
24
30
80.0
59
76
77.6
3,837
74.5
38,111
76.4
1684
30-59 cc/min
3
9
33.3
0
11
0.0
4
26
15.4
6
30
20.0
13
76
17.1
1,002
19.4
9,074
18.2
1685
<30 cc/min
1
9
11.1
2
11
18.2
1
26
3.9
0
30
0.0
4
76
5.3
261
5.1
2,306
4.6
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
71
1.4
689
1.4
1,561
38.4
16,893
41.8
528
57.0
5,754
57.4
1,144
73.3
12,216
72.4
154
5.1
1,792
5.6
1686
Initial hemoglobin < 9 g/dL
1687
Hemoglobin A1c
1688
Overall
1689
Among diabetes mellitus
1690
<7%
1691
INR>1.5
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
In-Hospital Events
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1692
Unadjusted death (9)
1693
Overall
1694
1695
1696
1697
1698
Num
Den
0
Lower 95% confidence limit
0.0
Upper 95% confidence limit
0.0
Excluding transfers in
0
%
9
0.0
Num
Den
1
%
11
9.1
0.0
0.0
1
Den
3
%
23
13.0
0.0
26.1
9
Num
9.1
Den
0
%
25
0.0
0.0
26.8
11
Num
20
15.0
0
Den
4
%
68
5.9
0.3
0.0
3
Num
0.0
4
%
345
6.9
6.2
11.5
20
Num
US Registry Pts
R4Q
6.7
278
%
2,969
6.4
7.6
2,101
Lower 95% confidence limit
0.0
0.0
0.0
0.0
0.4
6.7
6.1
Upper 95% confidence limit
0.0
26.1
30.7
0.0
13.0
8.4
6.7
1699
Risk adjusted death (9)
1700
Overall
7.0
5.9
0.0
1701
Lower 95% confidence limit
3.5
4.4
0.0
1702
Upper 95% confidence limit
13.8
8.0
0.0
7.4
6.3
0.0
1703
Excluding transfers in
6.2
6.0
7.6
60
Num
1704
Lower 95% confidence limit
3.7
4.6
0.0
1705
Upper 95% confidence limit
14.8
8.6
0.0
6.4
1706
Clinical events
1707
Reinfarction
0
9
0.0
0
10
0.0
0
20
0.0
0
25
0.0
0
64
0.0
41
0.9
360
0.8
1708
Cardiogenic shock
0
9
0.0
0
10
0.0
0
20
0.0
0
25
0.0
0
64
0.0
252
5.4
2,059
4.5
1709
Heart failure
0
9
0.0
0
10
0.0
0
20
0.0
0
25
0.0
0
64
0.0
250
5.3
2,361
5.2
1710
CVA/stroke
0
9
0.0
0
10
0.0
0
20
0.0
0
25
0.0
0
64
0.0
28
0.6
227
0.5
4
14.3
27
12.0
1711
Hemorrhagic stroke
1712
Cardiac arrest
1
9
11.1
1
10
10.0
0
20
0.0
1
25
4.0
3
64
4.7
163
3.5
1,475
3.2
1713
Any of above events
1
9
11.1
1
10
10.0
0
20
0.0
1
25
4.0
3
64
4.7
567
12.1
5,110
11.2
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Bleeding Events
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1714
Unadjusted bleeding events (9)
1715
Overall
1716
1717
1718
1719
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
%
349
Lower 95% confidence limit
8.5
Upper 95% confidence limit
10.4
Excluding transfers in
US Registry Pts
R4Q
252
9.4
Num
%
3,641
10.1
9.5
2,451
Lower 95% confidence limit
8.4
9.3
1720
Upper 95% confidence limit
10.6
10.0
1721
Risk adjusted bleeding events
(9)
1722
Overall
9.6
0.0
1723
Lower 95% confidence limit
8.3
0.0
1724
Upper 95% confidence limit
11.1
0.0
9.4
0.0
1725
Excluding transfers in
1726
Lower 95% confidence limit
8.0
0.0
1727
Upper 95% confidence limit
11.0
0.0
1728
Bleeding events
1729
Suspected bleeding event
9
11.1
0
11
0.0
0
26
0.0
0
30
0.0
1
76
1.3
9.7
202
3.9
1,863
3.7
1730
Access site
41
24.9
472
31.5
1731
Retroperitoneal
14
8.5
123
8.2
1732
GI
43
26.1
473
31.6
1733
GU
1734
Other
1735
1
9.8
9.5
Surgical intervention required
9
5.5
81
5.4
62
37.6
414
27.6
28
17.0
262
17.6
1736
Suspected bleeding Event
among non-CABG patient
1
9
11.1
0
11
0.0
0
26
0.0
0
30
0.0
1
76
1.3
169
3.2
1,637
3.2
1737
RBC/whole blood
transfusion
1
9
11.1
0
11
0.0
1
26
3.9
0
30
0.0
2
76
2.6
396
7.6
3,660
7.2
89.7
1738
Initial hemoglobin >=9 g/dL
1
1
100.0
1
1
100.0
2
2
100.0
363
91.9
3,271
1739
Initial hemoglobin <9 g/dL
0
1
0.0
0
1
0.0
0
2
0.0
32
8.1
376
10.3
935
26.7
8,756
25.6
1740
Hemoglobin drop >=3 g/dL
1741
CABG related transfusion
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
112
2.1
1,112
2.2
1742
Non-CABG related
transfusion
0
9
0.0
0
11
0.0
0
26
0.0
0
30
0.0
0
76
0.0
183
3.5
1,864
3.7
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Discharge Therapies
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
1743
Discharge therapies
1744
Medications
1745
Any oral antiplatelet
9
9
100.0
10
10
100.0
19
19
100.0
24
24
100.0
62
62
100.0
1746
Aspirin
9
9
100.0
9
9
100.0
16
16
100.0
24
24
100.0
58
58
100.0
1747
P2Y12
Num
US Registry Pts
R4Q
%
Num
%
4,506
99.2
44,307
99.1
4,129
99.5
40,805
99.0
62.9
1748
Clopidogrel
8
9
88.9
7
10
70.0
9
19
47.4
16
23
69.6
40
61
65.6
2,956
66.9
27,108
1749
Ticlopidine
0
9
0.0
0
10
0.0
0
19
0.0
1
23
4.4
1
61
1.6
4
0.1
49
0.1
1750
Prasugrel
1
9
11.1
3
10
30.0
9
19
47.4
7
24
29.2
20
62
32.3
1,114
25.0
12,893
29.7
1751
Among medically managed
patients (excl d/c on Warfarin)
171
57.2
1,743
59.2
1752
Among PCI patients (excl d/c
on Warfarin)
1753
Among CABG patients (excl
d/c on Warfarin)
9
9
100.0
9
9
100.0
16
16
100.0
23
24
95.8
57
58
98.3
3,600
97.0
35,431
96.6
0
1
0.0
0
1
0.0
83
33.3
959
43.8
1754
Warfarin
0
9
0.0
0
9
0.0
3
19
15.8
0
24
0.0
3
61
4.9
315
7.0
2,916
6.6
1755
Beta blocker
9
9
100.0
10
10
100.0
19
19
100.0
23
23
100.0
61
61
100.0
4,203
98.6
41,903
97.9
1756
ACE inhibitor
5
9
55.6
6
9
66.7
15
17
88.2
19
22
86.4
45
57
79.0
3,052
74.8
29,838
73.0
1757
Angiotensin receptor
blocker
0
9
0.0
1
9
11.1
1
19
5.3
0
24
0.0
2
61
3.3
369
8.7
3,488
8.4
1758
ACE/ARB among ideal
patients
2
2
100.0
1
2
50.0
3
4
75.0
603
91.8
7,514
91.8
1759
Aldosterone blocking agent
0
9
0.0
0
9
0.0
0
19
0.0
0
24
0.0
0
61
0.0
194
4.3
1,956
4.4
1760
Statin
9
9
100.0
10
10
100.0
18
18
100.0
24
24
100.0
61
61
100.0
4,292
99.2
42,281
99.1
1761
Non-statin lipid-lowering
agent
0
1
0.0
0
1
0.0
226
5.9
3,465
8.7
1762
Discharge recommendation
1763
Smoking counseling (among
smokers)
5
5
100.0
28
28
100.0
1,640
99.0
19,368
98.8
1764
Dietary modification
counseling
3,433
96.9
34,615
96.8
1765
Exercise counseling
9
9
100.0
10
10
100.0
19
19
100.0
24
24
100.0
62
62
100.0
4,014
89.4
37,719
86.0
1766
Cardiac rehab referral
3
9
33.3
8
10
80.0
16
19
84.2
22
24
91.7
49
62
79.0
3,180
77.1
35,069
84.3
1767
2
2
100.0
11
11
100.0
10
10
100.0
Discharge location
1768
Home
9
9
100.0
10
10
100.0
18
23
78.3
24
30
80.0
61
72
84.7
4,349
88.8
42,511
89.4
1769
Extended care/transitional
care unit
0
9
0.0
0
10
0.0
0
23
0.0
0
30
0.0
0
72
0.0
143
2.9
1,444
3.0
1770
Other hospital
0
9
0.0
0
10
0.0
3
23
13.0
5
30
16.7
8
72
11.1
190
3.9
1,785
3.8
1771
Nursing home
0
9
0.0
0
10
0.0
1
23
4.4
0
30
0.0
1
72
1.4
116
2.4
946
2.0
1772
Hospice
0
9
0.0
0
10
0.0
0
23
0.0
0
30
0.0
0
72
0.0
38
0.8
359
0.8
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
STEMI Patients
Discharge Therapies
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1773
Other
0
9
0.0
0
10
0.0
0
23
0.0
0
30
0.0
0
72
0.0
20
0.4
194
0.4
1774
Left against medical advice
(AMA)
0
9
0.0
0
10
0.0
1
23
4.4
1
30
3.3
2
72
2.8
41
0.8
329
0.7
94.0
1775
Discharge status
1776
Alive
9
9
100.0
10
11
90.9
23
26
88.5
30
30
100.0
72
76
94.7
4,897
93.4
47,574
1777
Deceased
0
9
0.0
1
11
9.1
3
26
11.5
0
30
0.0
4
76
5.3
348
6.6
3,030
6.0
0
9
0.0
0
11
0.0
1
26
3.9
0
30
0.0
1
76
1.3
255
4.9
1,689
3.3
1778
Comfort measures only
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Demographics and Payors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1779
Demographics
1780
Sex
1781
Male
1782
Female
1783
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
9
23
39.1
23
42
54.8
21
37
56.8
17
29
58.6
70
131
53.4
4,863
62.4
48,660
61.2
14
23
60.9
19
42
45.2
16
37
43.2
12
29
41.4
61
131
46.6
2,932
37.6
30,860
38.8
Age at admission
1784
Mean age
65
71
73
70
70
68
1785
Median age
64
75
73
65
70
68
1786
18-44
2
23
8.7
1
42
2.4
0
37
0.0
0
29
0.0
3
131
2.3
390
5.0
4,671
5.9
1787
45-54
4
23
17.4
6
42
14.3
3
37
8.1
1
29
3.5
14
131
10.7
996
12.8
12,042
15.1
1788
55-64
6
23
26.1
6
42
14.3
10
37
27.0
11
29
37.9
33
131
25.2
1,855
23.8
19,255
24.2
1789
65-69
0
23
0.0
3
42
7.1
4
37
10.8
5
29
17.2
12
131
9.2
1,027
13.2
10,022
12.6
1790
70-74
3
23
13.0
3
42
7.1
2
37
5.4
1
29
3.5
9
131
6.9
902
11.6
8,924
11.2
1791
75-79
2
23
8.7
8
42
19.1
6
37
16.2
3
29
10.3
19
131
14.5
836
10.7
8,143
10.2
1792
>= 80
6
23
26.1
15
42
35.7
12
37
32.4
8
29
27.6
41
131
31.3
1,789
23.0
16,463
20.7
1793
Medicare age ( >= 65)
11
23
47.8
29
42
69.1
24
37
64.9
17
29
58.6
81
131
61.8
4,554
58.4
43,552
54.8
1794
67
66
Race
1795
White
18
23
78.3
27
42
64.3
22
37
59.5
23
29
79.3
90
131
68.7
6,790
87.1
67,070
84.3
1796
Black/African American
4
23
17.4
4
42
9.5
10
37
27.0
4
29
13.8
22
131
16.8
302
3.9
10,054
12.6
1797
Asian
1
23
4.4
6
42
14.3
3
37
8.1
2
29
6.9
12
131
9.2
453
5.8
1,383
1.7
1798
American Indian/Alaskan
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
69
0.9
464
0.6
1799
Hawaiian/Pacific Islander
0
23
0.0
2
42
4.8
2
37
5.4
0
29
0.0
4
131
3.1
43
0.6
125
0.2
5
23
21.7
3
42
7.1
5
37
13.5
4
29
13.8
17
131
13.0
776
10.1
3,723
4.7
1800
Hispanic or Latino Ethnicity
1801
Insurance payors
1802
Private
11
23
47.8
17
42
40.5
17
37
46.0
12
29
41.4
57
131
43.5
4,283
55.0
44,621
56.1
1803
Medicare
13
23
56.5
33
42
78.6
24
37
64.9
19
29
65.5
89
131
67.9
4,416
56.7
45,262
56.9
1804
Medicaid
4
23
17.4
11
42
26.2
7
37
18.9
6
29
20.7
28
131
21.4
930
11.9
8,687
10.9
1805
Military
0
23
0.0
3
42
7.1
2
37
5.4
3
29
10.3
8
131
6.1
422
5.4
2,388
3.0
1806
State-specific (non-Medicaid)
0
23
0.0
0
42
0.0
2
37
5.4
1
29
3.5
3
131
2.3
258
3.3
1,061
1.3
1807
Indian Health Service
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
20
0.3
145
0.2
1808
Non-U.S Insurance
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
7
0.1
41
0.1
1809
None
3
23
13.0
1
42
2.4
2
37
5.4
3
29
10.3
9
131
6.9
566
7.3
7,395
9.3
0
23
0.0
0
42
0.0
2
37
5.4
1
29
3.5
3
131
2.3
2,113
27.1
22,113
27.8
23
23
100.0
42
42
100.0
35
37
94.6
28
29
96.6
128
131
97.7
5,682
72.9
57,407
72.2
1
23
4.4
2
42
4.8
3
37
8.1
3
29
10.3
9
131
6.9
170
2.2
3,748
4.7
21
23
91.3
35
42
83.3
32
37
86.5
22
29
75.9
110
131
84.0
7,319
93.9
73,002
91.8
1810
Transfers in
1811
Not Transferred in
1812
Transfers out
1813
Not transferred out
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Medical History/Home Medications
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1814
History and risk factors
1815
Current smoker (< 1 year)
1816
Hypertension
1817
Dyslipidemia
1818
Currently on dialysis
1819
Chronic lung disease
1820
Diabetes mellitus
1821
Diabetes therapy:
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
7
23
30.4
7
42
16.7
7
37
18.9
7
29
24.1
28
131
21.4
1,862
23.9
23,966
30.2
19
23
82.6
36
42
85.7
35
37
94.6
26
29
89.7
116
131
88.6
5,941
76.2
63,115
79.4
4,004
65.9
42,425
66.0
315
4.0
2,919
3.7
941
15.5
11,570
18.0
2
23
8.7
3
42
7.1
2
37
5.4
6
29
20.7
13
131
9.9
8
23
34.8
20
42
47.6
12
37
32.4
17
29
58.6
57
131
43.5
2,837
36.4
30,155
38.0
5.6
1822
None
0
8
0.0
0
20
0.0
0
12
0.0
0
17
0.0
0
57
0.0
160
5.6
1,689
1823
Diet
0
8
0.0
0
20
0.0
0
12
0.0
0
17
0.0
0
57
0.0
174
6.1
1,536
5.1
1824
Oral
0
8
0.0
0
20
0.0
0
12
0.0
0
17
0.0
0
57
0.0
957
33.7
11,042
36.6
1825
Insulin
0
8
0.0
0
20
0.0
0
12
0.0
0
17
0.0
0
57
0.0
832
29.3
9,846
32.7
1826
Other
0
8
0.0
0
20
0.0
0
12
0.0
0
17
0.0
0
57
0.0
32
1.1
140
0.5
1827
Obesity (BMI >= 30)
2,339
38.7
26,275
41.2
1828
Prior MI
1,780
29.3
19,042
29.6
1829
Prior Heart Failure
948
15.6
11,303
17.6
1830
Prior PCI
1,514
24.9
17,739
27.6
1831
Prior CABG
999
16.4
11,937
18.6
1832
Atrial fibrillation or flutter
(past 2 weeks)
523
8.6
5,960
9.3
1833
Cerebrovascular disease
14.9
1834
Prior stroke
1835
Peripheral arterial disease
0
23
0.0
3
42
7.1
7
37
18.9
5
29
17.2
15
131
11.5
1,103
14.2
11,811
0
23
0.0
3
42
7.1
7
37
18.9
4
29
13.8
14
131
10.7
687
8.8
7,686
9.7
1
23
4.4
4
41
9.8
3
37
8.1
5
29
17.2
13
130
10.0
801
10.3
9,611
12.1
1836
Home medications
1837
Aspirin
2,933
48.3
32,124
50.0
1838
Clopidogrel
791
13.0
11,557
18.0
1839
Ticlopidine
2
0.0
74
0.1
1840
Prasugrel
50
0.8
777
1.2
1841
Warfarin
362
6.0
4,066
6.3
1842
Beta blocker
2,488
40.9
29,208
45.5
1843
ACE inhibitor
1,768
29.1
20,719
32.3
1844
Angiotensin receptor
blocker
748
12.3
7,877
12.3
1845
Aldosterone blocking agent
1846
Statin
1847
Non-statin lipid-lowering
agent
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
165
2.7
1,776
2.8
2,701
44.5
29,606
46.1
506
8.3
6,681
10.4
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Hospital Presentation
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1848
Hospital presentation
1849
Means of transport (first
facility)
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1850
Self/family
11
23
47.8
23
42
54.8
12
37
32.4
13
29
44.8
59
131
45.0
4,476
57.4
46,884
59.0
1851
Ambulance
12
23
52.2
19
42
45.2
25
37
67.6
16
29
55.2
72
131
55.0
3,268
41.9
31,921
40.2
1852
Mobile ICU
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
9
0.1
415
0.5
1853
Air
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
41
0.5
225
0.3
1854
Means of transfer (outside
facility)
1855
Ambulance
2
2
100.0
1
1
100.0
3
3
100.0
1,529
72.7
18,549
84.2
1856
Mobile ICU
0
2
0.0
0
1
0.0
0
3
0.0
77
3.7
1,379
6.3
1857
Air
0
2
0.0
0
1
0.0
0
3
0.0
498
23.7
2,106
9.6
4,475
73.7
47,646
74.2
1858
1859
1860
Location of first evaluation
ED
Median hours from arrival to
transfer from ED
1861
Cath lab
1862
Other
1863
3.6
3.9
258
4.3
2,386
3.7
1,341
22.1
14,206
22.1
First ECG obtained
1864
Pre hospital (3)
6
23
26.1
10
42
23.8
14
35
40.0
9
28
32.1
39
128
30.5
1,404
24.7
11,749
20.5
1865
After 1st hospital arrival
17
23
73.9
32
42
76.2
21
35
60.0
19
28
67.9
89
128
69.5
4,272
75.3
45,590
79.5
1866
Median time to 1st ECG
10.0
1867
ECG less than or equal to 10
min of presentation
1868
11.0
11.0
7.0
10.0
8.0
9.0
10
17
58.8
16
32
50.0
10
21
47.6
12
19
63.2
48
89
53.9
2,523
59.3
26,579
58.4
Other ECG findings
1869
New or presumed new ST
depression
4
23
17.4
7
42
16.7
5
35
14.3
5
29
17.2
21
129
16.3
1,879
24.2
15,701
19.8
1870
New or presumed new T-wave
inversion
3
23
13.0
5
42
11.9
5
35
14.3
5
29
17.2
18
129
14.0
1,212
15.6
10,324
13.0
1871
Transient ST elevation lasting
<20 min
1
23
4.4
5
42
11.9
0
35
0.0
0
29
0.0
6
129
4.7
217
2.8
1,612
2.0
15
23
65.2
25
42
59.5
25
35
71.4
19
29
65.5
84
129
65.1
4,444
57.3
51,559
65.1
1872
1873
None
Median time from symptom
onset to presentation
(hours) (2)
1874
>= 6 hours
1875
< 6 hours
1876
2.2
4.1
3.2
5.0
3.1
2.4
2.4
7
23
30.4
16
42
38.1
13
35
37.1
11
28
39.3
47
128
36.7
1,157
23.1
10,782
22.6
16
23
69.6
26
42
61.9
22
35
62.9
17
28
60.7
81
128
63.3
3,578
71.3
33,013
69.3
Cardiac status on first medical
contact
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Hospital Presentation
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1877
Heart failure
7
23
30.4
16
42
38.1
15
37
40.5
11
29
37.9
49
131
37.4
1,325
17.0
14,246
17.9
1878
Cardiogenic shock
1
23
4.4
1
41
2.4
2
37
5.4
0
29
0.0
4
130
3.1
192
2.5
1,477
1.9
1879
Hypotension
2
23
8.7
1
42
2.4
1
37
2.7
1
29
3.5
5
131
3.8
260
3.3
2,422
3.1
1880
Tachycardia
7
23
30.4
13
42
31.0
13
37
35.1
6
29
20.7
39
131
29.8
1,702
21.9
18,172
22.9
1881
Cocaine use
36
0.6
600
0.9
1882
Cardiac arrest
1
23
4.4
0
42
0.0
2
37
5.4
0
29
0.0
3
131
2.3
172
2.2
1,379
1.8
1883
Pre-hospital
1
1
100.0
2
2
100.0
3
3
100.0
127
73.8
1,025
74.3
1884
Outside Facility
0
1
0.0
0
2
0.0
0
3
0.0
30
17.4
248
18.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Acute and In-Hospital Medications and Dosing Errors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
%
Num
%
6,995
97.7
71,675
97.9
7,330
97.1
75,036
97.3
46.5
3,353
45.5
36,055
47.7
131
0.0
3
0.0
48
0.1
7
130
5.4
734
9.7
6,730
8.8
94
114
82.5
5,667
83.7
60,620
84.7
2,112
39.7
22,407
38.9
508
9.2
5,245
8.8
1885
Acute and in-hospital
medications and dosing errors
1886
Any acute oral antiplatelet
19
21
90.5
40
41
97.6
35
35
100.0
27
28
96.4
121
125
96.8
1887
Aspirin
18
21
85.7
41
42
97.6
35
36
97.2
28
29
96.6
122
128
95.3
1888
Clopidogrel
13
23
56.5
22
41
53.7
14
36
38.9
11
29
37.9
60
129
1889
Ticlopidine
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
1890
Prasugrel
1
23
4.4
3
42
7.1
1
37
2.7
2
28
7.1
1891
Beta blocker
14
19
73.7
26
34
76.5
27
33
81.8
27
28
96.4
1892
ACE inhibitor
1893
Angiotensin receptor
blocker
1894
Aldosterone blocking agent
1895
Statin
1896
Non-statin lipid-lowering
agent
1897
GP IIb/IIIa inhibitor
1898
0
23
0.0
Eptifibatide
Num
US Registry Pts
R4Q
130
2.2
1,415
2.2
3,713
64.2
38,759
62.7
272
4.5
4,351
6.8
3
41
7.3
1
37
2.7
1
29
3.5
5
130
3.9
1,464
19.2
17,923
23.2
3
3
100.0
1
1
100.0
1
1
100.0
5
5
100.0
1,166
79.6
16,249
90.7
1899
Full dose
758
79.8
11,452
84.0
1900
Reduced dose
126
13.3
1,408
10.3
1901
Other
64
6.7
712
5.2
165
11.3
433
2.4
78.8
1902
Tirofiban
1903
Full dose
97
58.8
323
1904
Reduced dose
15
9.1
27
6.6
1905
Other
50
30.3
56
13.7
1906
Abciximab
3
0.0
0
1
0.0
0
1
0.0
0
5
0.0
0
3
0.0
0
1
0.0
0
1
0.0
0
5
0.0
127
8.7
1,206
6.7
2
24
8.3
1
12
8.3
1
9
11.1
4
54
7.4
1,212
32.6
13,800
37.9
Started infusion pre-PCI (4)
0
2
0.0
1
1
100.0
0
1
0.0
1
4
25.0
270
22.3
4,480
32.5
Started infusion peri-PCI (5)
2
2
100.0
0
1
0.0
1
1
100.0
3
4
75.0
933
77.0
9,256
67.1
38
41
92.7
31
36
86.1
27
28
96.4
116
128
90.6
6,859
89.6
71,790
92.0
1907
Any GP IIb-IIIa inhibitor
among PCI patients
1908
1909
1910
0
Anticoagulant
0
9
0.0
20
23
87.0
1911
IV unfractionated heparin
9
20
45.0
8
38
21.1
11
31
35.5
16
27
59.3
44
116
37.9
4,412
64.3
47,366
66.0
1912
LMWH
11
20
55.0
29
38
76.3
21
31
67.7
23
27
85.2
84
116
72.4
2,862
41.7
30,366
42.3
1913
Enoxaparin
11
20
55.0
29
38
76.3
21
31
67.7
23
27
85.2
84
116
72.4
2,584
37.7
29,383
40.9
166
8.6
1,500
6.3
1914
Initial IV bolus
1915
SubQ doses
1916
q 12 hours
762
39.2
10,426
43.7
1917
q 24 hours
433
22.3
5,679
23.8
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Acute and In-Hospital Medications and Dosing Errors
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1918
Dalteparin
0
20
0.0
0
38
0.0
0
31
0.0
0
27
0.0
0
116
0.0
319
4.7
1,106
1919
Fondaparinux
0
20
0.0
0
38
0.0
0
31
0.0
0
27
0.0
0
116
0.0
26
0.4
376
0.5
1920
Direct thrombin inhibitors
7
20
35.0
20
38
52.6
11
31
35.5
7
27
25.9
45
116
38.8
2,103
30.7
19,620
27.3
1921
Bivalirudin
7
20
35.0
20
38
52.6
11
31
35.5
7
27
25.9
45
116
38.8
2,099
30.6
19,559
27.2
1922
Argatroban
0
20
0.0
0
38
0.0
0
31
0.0
0
27
0.0
0
116
0.0
7
0.1
68
0.1
1923
Lepirudin
0
20
0.0
0
38
0.0
0
31
0.0
0
27
0.0
0
116
0.0
2
0.0
11
0.0
936
50.0
10,591
48.1
1924
Dosing errors for
anticoagulants and GP IIbIIIa inhibitors
1925
Heparin, IV UFH-overall (All
AMI)
1.5
1926
Bolus
801
85.6
8,222
77.6
1927
Infusion
428
45.7
5,588
52.8
1928
Enoxaparin-overall
1929
Initial Dose > 1.05 mg/kg
178
14.4
1,765
11.5
1930
GP IIb-IIIa Inhibitor (All
AMI)
47
4.9
833
6.8
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
In-Hospital Procedures
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1931
In-hospital procedures
1932
Non-invasive stress test
1933
Diagnostic coronary
angiography
1934
Cath without prior noninvasive stress testing
1935
Diagnostic cath results
Num
Den
15
%
23
65.2
Num
Den
33
%
42
78.6
Num
Den
23
%
37
62.2
Num
Den
22
%
29
75.9
Num
Den
93
%
131
71.0
Num
US Registry Pts
R4Q
%
Num
%
387
6.4
3,809
5.9
6,150
79.0
62,995
79.3
4,663
96.2
49,027
95.6
1936
Non-obstructive CAD - all
vessels <50%
349
8.4
4,149
9.8
1937
Pt with no CAD (all native
vessels <=10% stenosis)
(w/o CABG)
204
4.9
2,232
5.2
1938
Diseased vessels
(including LM disease)
1939
LM disease (>=50%)
520
10.7
5,608
10.9
1940
LM and RCA disease (triple
vessel)
369
7.6
3,922
7.6
1941
LM w/out RCA disease
(double vessel)
151
3.1
1,686
3.3
1942
Diseased vessel w/or w/o
LM
1943
Single vessel disease
1,731
35.7
18,147
35.3
1944
Double vessel disease
1,344
27.7
14,321
27.9
1945
Triple vessel disease
1,273
26.3
12,814
24.9
1946
LV function
1947
Normal (EF >=50%)
12
23
52.2
22
42
52.4
16
37
43.2
16
29
55.2
66
131
50.4
4,557
58.5
43,797
55.1
1948
Mildly reduced (EF 40-49%)
4
23
17.4
9
42
21.4
9
37
24.3
9
29
31.0
31
131
23.7
1,285
16.5
13,718
17.3
1949
Moderately reduced (EF
25-39%)
5
23
21.7
5
42
11.9
6
37
16.2
3
29
10.3
19
131
14.5
954
12.2
11,249
14.2
1950
Severely reduced (EF <25%)
1
23
4.4
2
42
4.8
5
37
13.5
0
29
0.0
8
131
6.1
286
3.7
3,998
5.0
1951
Not Assessed
1
23
4.4
4
42
9.5
1
37
2.7
1
29
3.5
7
131
5.3
696
8.9
6,479
8.2
9
21
42.9
22
35
62.9
10
32
31.3
8
22
36.4
49
110
44.6
3,651
49.9
36,094
49.5
1952
Revascularization status
(6)
1953
PCI
1954
Stent type
1955
Bare metal stent
2
6
33.3
2
21
9.5
5
9
55.6
3
8
37.5
12
44
27.3
819
24.1
8,715
25.9
1956
Drug eluting stent
4
6
66.7
19
21
90.5
4
9
44.4
5
8
62.5
32
44
72.7
2,609
76.6
25,060
74.4
1957
Other
0
6
0.0
0
21
0.0
0
9
0.0
0
8
0.0
0
44
0.0
3
0.1
150
0.5
1958
CABG
0
21
0.0
2
35
5.7
4
32
12.5
4
22
18.2
10
110
9.1
884
12.1
7,679
10.5
12
21
57.1
12
35
34.3
18
32
56.3
10
22
45.5
52
110
47.3
2,833
38.7
29,595
40.5
1959
No revascularization
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Reperfusion Use
Sample Hospital
2011Q3
2011Q4
2012Q1
2012Q2
My Hospital R4Q
Line#
Description
1960
Reperfusion use
1961
PCI indications
1962
PCI for NSTEMI
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Num
Den
9
%
9
100.0
Num
24
Den
%
24
100.0
Num
Den
12
%
12
Rev: 5
100.0
Num
Den
9
%
9
100.0
Num
54
Den
%
54
100.0
US
Comparison
Group Pts
R4Q
Num
3,604
US Registry Pts
R4Q
%
96.3
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Num
35,752
%
97.0
NSTEMI Patients
Early Invasive Management
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
1963
Early invasive management
1964
Early catheterization
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1965
Within 48 hours
0
15
0.0
0
33
0.0
0
23
0.0
0
22
0.0
0
93
0.0
4,322
70.3
42,624
67.7
1966
Within 24 hours
0
15
0.0
0
33
0.0
0
23
0.0
0
22
0.0
0
93
0.0
3,509
57.1
32,058
50.9
1967
Early percutaneous
intervention (7)
1968
Within 48 hours
0
9
0.0
0
22
0.0
0
10
0.0
0
8
0.0
0
49
0.0
2,675
73.3
25,645
71.1
1969
Within 24 hours
0
9
0.0
0
22
0.0
0
10
0.0
0
8
0.0
0
49
0.0
2,241
61.4
20,120
55.7
42.5
1970
Acute antiplatelet therapy
among admissions with
early cath (8)
1971
P2Y12 only, %
1,841
44.9
17,125
1972
GP IIb-IIIa inhibitor only, %
296
7.2
3,631
9.0
1973
P2Y12 and GPI, %
793
19.3
8,769
21.7
1,170
28.5
10,803
26.8
1974
1975
Neither P2Y12 nor GPI, %
Median time from hospital
presentation until…(hours)
1976
Non-transfer in
1977
Diagnostic catheterization
1978
PCI
1979
CABG
1980
Transfer in
1981
Diagnostic catheterization
1982
PCI
1983
CABG
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
9.3
18.9
22.3
23.9
15.2
20.0
15.2
Rev: 5
17.2
21.1
17.3
20.2
77.2
81.7
10.4
12.9
10.4
11.8
64.6
67.1
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Laboratory Results
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
1984
Laboratory results
1985
Positive cardiac markers
within first 24 hours
23
23
100.0
42
42
100.0
37
37
100.0
29
29
100.0
131
131
100.0
7,795
100.0
79,520
100.0
1986
Initial troponin
23
23
100.0
42
42
100.0
37
37
100.0
29
29
100.0
131
131
100.0
7,768
99.7
79,334
99.8
1987
Initial CK-MB
3,281
54.0
47,786
74.4
1988
Lipids
13
23
56.5
27
42
64.3
18
37
48.7
17
29
58.6
75
131
57.3
5,931
76.2
62,469
78.6
76.0
1989
Drawn in hospital
0
13
0.0
0
27
0.0
0
18
0.0
0
17
0.0
0
75
0.0
4,376
73.8
47,468
1990
Drawn prior to admission
0
13
0.0
0
27
0.0
0
18
0.0
0
17
0.0
0
75
0.0
245
4.1
3,234
5.2
1991
HDL <40 mg/dL
2,614
56.3
28,123
55.6
1992
LDL <70 mg/dL
4
13
30.8
5
27
18.5
6
18
33.3
6
17
35.3
21
75
28.0
1,558
26.8
16,190
26.5
1993
LDL >= 70 to <= 100
6
13
46.2
12
27
44.4
5
18
27.8
5
17
29.4
28
75
37.3
1,873
32.2
19,174
31.4
1994
LDL >100 mg/dL
3
13
23.1
10
27
37.0
7
18
38.9
6
17
35.3
26
75
34.7
2,391
41.1
25,780
42.2
1995
Triglycerides >300 mg/dL
376
8.1
4,060
8.0
2,851
46.9
31,371
48.8
1996
BNP or NTproBNP collected
1997
Initial creatinine clearance
1998
>=60 cc/min
11
23
47.8
14
42
33.3
16
37
43.2
12
29
41.4
53
131
40.5
4,641
59.9
49,444
62.6
1999
30-59 cc/min
7
23
30.4
13
42
31.0
13
37
35.1
7
29
24.1
40
131
30.5
2,057
26.5
19,786
25.1
2000
<30 cc/min
5
23
21.7
13
42
31.0
8
37
21.6
10
29
34.5
36
131
27.5
980
12.7
9,081
11.5
1
23
4.4
4
42
9.5
0
37
0.0
2
29
6.9
7
131
5.3
198
2.6
2,447
3.1
2001
Initial hemoglobin < 9 g/dL
2002
Hemoglobin A1c
2003
Overall
2,185
36.0
25,175
39.2
2004
Among diabetes mellitus
1,082
50.2
12,753
52.5
2005
<7%
1,440
66.0
16,518
65.7
348
8.3
3,598
7.0
2006
INR>1.5
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
In-Hospital Events
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
2007
Unadjusted death (9)
2008
Overall
2009
2010
2011
2012
2013
Num
Den
1
Lower 95% confidence limit
0.0
Upper 95% confidence limit
13.3
Excluding transfers in
1
%
22
4.6
Num
Den
5
%
40
12.5
2.3
4.6
5
Den
1
%
34
2.9
0.0
22.8
22
Num
12.5
Den
4
%
26
15.4
1.5
8.6
40
Num
32
3.1
3
Den
11
%
122
9.0
3.9
29.3
1
Num
12.0
10
%
300
4.0
3.5
14.1
25
Num
US Registry Pts
R4Q
8.4
242
%
2,673
3.7
4.4
1,976
Lower 95% confidence limit
0.0
2.3
0.0
0.0
3.4
3.9
3.6
Upper 95% confidence limit
13.3
22.8
9.2
24.7
13.4
4.9
3.9
2014
Risk adjusted death (9)
2015
Overall
4.7
4.0
0.0
2016
Lower 95% confidence limit
2.9
3.3
0.0
2017
Upper 95% confidence limit
7.6
5.0
0.0
4.8
4.2
0.0
2018
Excluding transfers in
3.6
3.5
4.4
119
Num
2019
Lower 95% confidence limit
2.9
3.3
0.0
2020
Upper 95% confidence limit
7.9
5.3
0.0
3.7
2021
Clinical events
2022
Reinfarction
0
21
0.0
0
35
0.0
0
32
0.0
0
21
0.0
0
109
0.0
61
0.8
438
0.6
2023
Cardiogenic shock
0
21
0.0
1
35
2.9
2
32
6.3
0
22
0.0
3
110
2.7
178
2.4
1,285
1.8
2024
Heart failure
0
21
0.0
0
35
0.0
1
32
3.1
0
22
0.0
1
110
0.9
403
5.5
3,785
5.2
2025
CVA/stroke
0
21
0.0
0
35
0.0
0
32
0.0
1
22
4.6
1
110
0.9
44
0.6
422
0.6
0
1
0.0
0
1
0.0
7
15.9
44
10.5
2026
Hemorrhagic stroke
2027
Cardiac arrest
0
20
0.0
0
35
0.0
2
32
6.3
0
22
0.0
2
109
1.8
70
1.0
596
0.8
2028
Any of above events
0
21
0.0
1
35
2.9
4
32
12.5
1
22
4.6
6
110
5.5
612
8.4
5,543
7.6
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Bleeding Events
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
2029
Unadjusted bleeding events (9)
2030
Overall
2031
2032
2033
2034
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
%
418
Lower 95% confidence limit
US Registry Pts
R4Q
7.1
6.5
Upper 95% confidence limit
307
%
4,369
7.5
7.5
3,111
Lower 95% confidence limit
6.7
7.1
2035
Upper 95% confidence limit
8.3
7.6
2036
Risk adjusted bleeding events
(9)
2037
Overall
7.0
0.0
2038
Lower 95% confidence limit
5.7
0.0
2039
Upper 95% confidence limit
8.6
0.0
6.9
0.0
2040
Excluding transfers in
2041
Lower 95% confidence limit
5.6
0.0
2042
Upper 95% confidence limit
8.6
0.0
2043
Bleeding events
2044
Suspected bleeding event
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
7.4
252
3.2
2,325
2.9
2045
Access site
31
15.7
390
21.6
2046
Retroperitoneal
16
8.1
111
6.1
2047
GI
53
26.9
700
38.7
2048
GU
10
5.1
99
5.5
2049
Other
93
47.2
558
30.9
2050
0
7.3
7.1
7.8
Excluding transfers in
Num
37
19.0
392
21.8
2051
Suspected bleeding Event
among non-CABG patient
Surgical intervention required
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
173
2.2
1,769
2.2
2052
RBC/whole blood
transfusion
4
23
17.4
7
42
16.7
6
37
16.2
4
29
13.8
21
131
16.0
931
12.0
8,646
10.9
80.7
2053
Initial hemoglobin >=9 g/dL
3
4
75.0
3
7
42.9
6
6
100.0
3
4
75.0
15
21
71.4
781
84.1
6,961
2054
Initial hemoglobin <9 g/dL
1
4
25.0
4
7
57.1
0
6
0.0
1
4
25.0
6
21
28.6
148
15.9
1,668
19.3
1,165
22.8
11,255
21.0
2055
Hemoglobin drop >=3 g/dL
2056
CABG related transfusion
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
315
4.1
2,962
3.7
2057
Non-CABG related
transfusion
0
23
0.0
0
42
0.0
0
37
0.0
0
29
0.0
0
131
0.0
359
4.6
4,025
5.1
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Discharge Therapies
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
2058
Discharge therapies
2059
Medications
2060
Any oral antiplatelet
20
20
100.0
33
33
100.0
28
30
93.3
22
22
100.0
103
105
98.1
2061
Aspirin
18
19
94.7
31
31
100.0
25
25
100.0
19
19
100.0
93
94
98.9
2062
P2Y12
Num
US Registry Pts
R4Q
%
Num
%
6,736
97.4
68,213
97.5
6,102
98.1
61,367
98.0
60.9
2063
Clopidogrel
17
20
85.0
22
32
68.8
16
29
55.2
8
22
36.4
63
103
61.2
3,992
60.1
40,534
2064
Ticlopidine
0
20
0.0
0
31
0.0
0
30
0.0
0
22
0.0
0
103
0.0
4
0.1
97
0.1
2065
Prasugrel
0
20
0.0
3
32
9.4
2
30
6.7
5
22
22.7
10
104
9.6
859
12.7
9,280
13.8
2066
Among medically managed
patients (excl d/c on Warfarin)
8
11
72.7
6
11
54.6
7
15
46.7
5
7
71.4
26
44
59.1
1,124
50.9
12,731
55.1
2067
Among PCI patients (excl d/c
on Warfarin)
9
9
100.0
18
19
94.7
10
10
100.0
8
8
100.0
45
46
97.8
3,269
97.7
32,152
97.0
2068
Among CABG patients (excl
d/c on Warfarin)
0
2
0.0
0
3
0.0
0
4
0.0
0
9
0.0
220
29.1
2,327
36.3
2069
Warfarin
0
20
0.0
0
31
0.0
2
30
6.7
3
22
13.6
5
103
4.9
529
7.7
5,867
8.5
2070
Beta blocker
18
19
94.7
29
29
100.0
25
25
100.0
21
21
100.0
93
94
98.9
6,201
96.4
63,963
96.5
2071
ACE inhibitor
14
18
77.8
19
30
63.3
18
26
69.2
18
20
90.0
69
94
73.4
3,663
60.5
37,991
60.7
2072
Angiotensin receptor
blocker
0
18
0.0
5
31
16.1
2
27
7.4
0
21
0.0
7
97
7.2
855
13.7
8,068
12.6
2073
ACE/ARB among ideal
patients
3
3
100.0
4
5
80.0
6
7
85.7
1
1
100.0
14
16
87.5
730
88.9
9,321
87.4
2074
Aldosterone blocking agent
0
20
0.0
0
30
0.0
0
30
0.0
0
22
0.0
0
102
0.0
339
4.9
2,956
4.3
2075
Statin
19
19
100.0
29
29
100.0
30
30
100.0
21
21
100.0
99
99
100.0
6,237
98.6
62,813
98.2
2076
Non-statin lipid-lowering
agent
530
8.9
7,555
12.1
2077
Discharge recommendation
2078
Smoking counseling (among
smokers)
1,671
97.4
21,500
98.2
2079
Dietary modification
counseling
5,110
94.7
53,478
95.0
2080
Exercise counseling
2081
Cardiac rehab referral
2082
6
6
100.0
6
6
100.0
6
6
100.0
6
6
100.0
24
24
100.0
18
20
90.0
33
33
100.0
30
30
100.0
22
22
100.0
103
105
98.1
5,825
86.1
55,290
82.7
8
20
40.0
20
33
60.6
13
25
52.0
16
18
88.9
57
96
59.4
3,842
64.6
44,994
73.4
Discharge location
2083
Home
17
22
77.3
30
37
81.1
24
35
68.6
20
25
80.0
91
119
76.5
6,337
84.6
63,611
82.9
2084
Extended care/transitional
care unit
0
22
0.0
0
37
0.0
0
35
0.0
0
25
0.0
0
119
0.0
379
5.1
3,697
4.8
2085
Other hospital
1
22
4.6
2
37
5.4
3
35
8.6
3
25
12.0
9
119
7.6
170
2.3
3,748
4.9
2086
Nursing home
3
22
13.6
4
37
10.8
8
35
22.9
2
25
8.0
17
119
14.3
370
4.9
3,599
4.7
2087
Hospice
0
22
0.0
0
37
0.0
0
35
0.0
0
25
0.0
0
119
0.0
131
1.8
1,114
1.5
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
NSTEMI Patients
Discharge Therapies
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
2088
Other
0
22
0.0
0
37
0.0
0
35
0.0
0
25
0.0
0
119
0.0
34
0.5
434
0.6
2089
Left against medical advice
(AMA)
1
22
4.6
1
37
2.7
0
35
0.0
0
25
0.0
2
119
1.7
68
0.9
547
0.7
22
23
95.7
37
42
88.1
36
37
97.3
25
29
86.2
120
131
91.6
7,492
96.1
76,764
96.5
1
23
4.4
5
42
11.9
1
37
2.7
4
29
13.8
11
131
8.4
303
3.9
2,756
3.5
0
23
0.0
2
42
4.8
3
37
8.1
3
29
10.3
8
131
6.1
391
5.0
2,970
3.7
2090
Discharge status
2091
Alive
2092
Deceased
2093
Comfort measures only
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute Therapies by Race
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
2094
Acute therapies (within 24
hours)
2095
Aspirin at arrival (White)
23
25
92.0
36
37
97.3
40
41
97.6
41
42
97.6
140
145
96.6
10,873
97.8
105,619
97.8
2096
Aspirin at arrival (Black)
4
4
100.0
4
4
100.0
12
13
92.3
13
13
100.0
33
34
97.1
453
98.5
14,425
97.5
2097
Aspirin at arrival (Other)
0
1
0.0
9
9
100.0
8
8
100.0
4
4
100.0
21
22
95.5
841
96.4
3,203
97.0
2098
Clopidogrel (White)
17
27
63.0
25
37
67.6
18
41
43.9
22
41
53.7
82
146
56.2
5,860
54.0
57,352
54.3
2099
Clopidogrel (Black)
4
4
100.0
1
4
25.0
7
13
53.9
8
13
61.5
20
34
58.8
236
52.0
7,878
53.9
2100
Clopidogrel (Other)
0
1
0.0
3
8
37.5
3
7
42.9
2
4
50.0
8
20
40.0
419
49.1
1,687
52.2
2101
Acute Anticoagulant (White)
25
27
92.6
33
36
91.7
37
42
88.1
40
41
97.6
135
146
92.5
10,440
92.7
102,272
93.6
2102
Acute Anticoagulant (Black)
4
4
100.0
4
4
100.0
11
12
91.7
13
13
100.0
32
33
97.0
421
90.0
13,797
91.9
2103
Acute Anticoagulant (Other)
0
1
0.0
9
9
100.0
7
8
87.5
4
4
100.0
20
22
90.9
776
86.8
3,083
92.0
2104
Acute GP IIb-IIIa Inh.
(White)
3
27
11.1
4
36
11.1
7
42
16.7
4
42
9.5
18
147
12.2
3,270
29.1
37,562
34.7
2105
Acute GP IIb-IIIa Inh.
(Black)
0
4
0.0
0
4
0.0
0
13
0.0
0
13
0.0
0
34
0.0
138
29.6
4,612
31.0
2106
Acute GP IIb-IIIa Inh.
(Other)
0
1
0.0
2
9
22.2
0
8
0.0
0
4
0.0
2
22
9.1
251
28.0
1,157
34.7
2107
Reperfusion (White)
9
9
100.0
10
10
100.0
18
20
90.0
19
19
100.0
56
58
96.6
3,980
86.5
37,009
84.9
2108
Reperfusion (Black)
3
3
100.0
9
9
100.0
12
12
100.0
147
84.5
4,084
79.2
2109
Reperfusion (Other)
2110
Time to PCI <= 90 (White)
2111
Time to PCI <= 90 (Black)
2112
Time to PCI <= 90 (Other)
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
5
7
71.4
1
1
100.0
3
3
100.0
2
2
100.0
6
6
100.0
282
79.2
1,174
81.1
9
10
90.0
15
15
100.0
16
17
94.1
45
49
91.8
2,462
94.5
21,739
94.8
2
2
100.0
6
6
100.0
8
8
100.0
101
94.4
2,475
92.7
3
3
100.0
2
2
100.0
6
6
100.0
188
94.0
737
94.0
1
1
100.0
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Discharge Therapies by Race
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
2113
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
Discharge therapies
2114
Aspirin (White)
22
23
95.7
29
29
100.0
27
27
100.0
29
29
100.0
107
108
99.1
8,978
98.7
86,991
98.5
2115
Aspirin (Black)
4
4
100.0
3
3
100.0
7
7
100.0
11
11
100.0
25
25
100.0
375
98.9
12,014
97.9
2116
Aspirin (Other)
1
1
100.0
6
6
100.0
7
7
100.0
3
3
100.0
17
17
100.0
699
98.2
2,638
98.2
2117
Clopidogrel (White)
21
24
87.5
23
30
76.7
16
33
48.5
16
31
51.6
76
118
64.4
6,115
63.1
57,710
61.8
2118
Clopidogrel (Black)
4
4
100.0
1
3
33.3
5
9
55.6
7
11
63.6
17
27
63.0
245
60.8
7,910
61.3
2119
Clopidogrel (Other)
0
1
0.0
3
6
50.0
4
6
66.7
1
3
33.3
8
16
50.0
453
60.7
1,670
59.4
2120
Beta blocker (White)
22
23
95.7
28
28
100.0
29
29
100.0
30
30
100.0
109
110
99.1
9,114
97.2
90,233
97.1
2121
Beta blocker (Black)
4
4
100.0
2
2
100.0
8
8
100.0
11
11
100.0
25
25
100.0
382
97.7
12,406
96.9
2122
Beta blocker (Other)
1
1
100.0
6
6
100.0
7
7
100.0
3
3
100.0
17
17
100.0
712
97.0
2,670
96.7
2123
ACE inhibitor or ARB (White)
3
3
100.0
6
7
85.7
5
6
83.3
1
1
100.0
15
17
88.2
1,146
90.0
14,077
89.3
2124
ACE inhibitor or ARB (Black)
1
1
100.0
1
1
100.0
48
87.3
2,244
90.1
2125
ACE inhibitor or ARB (Other)
1
2
50.0
1
2
50.0
108
91.5
425
87.5
2126
Statin (White)
23
23
100.0
28
28
100.0
32
32
100.0
31
31
100.0
114
114
100.0
9,241
98.9
89,542
98.6
2127
Statin (Black)
4
4
100.0
2
2
100.0
9
9
100.0
11
11
100.0
26
26
100.0
384
98.2
12,336
98.5
2128
Statin (Other)
1
1
100.0
7
7
100.0
7
7
100.0
3
3
100.0
18
18
100.0
704
99.0
2,654
98.7
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute and Discharge Therapies by Gender
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
2129
Acute therapies (within 24
hours)
2130
ECG <= to 10 min of pres
(Male)
10
12
83.3
9
18
50.0
13
17
76.5
13
17
76.5
45
64
70.3
2,840
68.7
28,419
67.9
2131
ECG <= to 10 min of pres
(Female)
8
13
61.5
11
19
57.9
4
11
36.4
7
10
70.0
30
53
56.6
1,261
57.3
13,300
55.6
2132
Aspirin at arrival (Male)
13
15
86.7
30
30
100.0
39
41
95.1
40
40
100.0
122
126
96.8
8,307
98.0
81,025
98.0
2133
Aspirin at arrival (Female)
14
15
93.3
22
23
95.7
21
21
100.0
18
19
94.7
75
78
96.2
4,098
97.2
42,910
97.2
2134
Clopidogrel (Male)
11
15
73.3
18
29
62.1
19
39
48.7
21
39
53.9
69
122
56.6
4,479
54.2
43,989
54.5
2135
Clopidogrel (Female)
10
17
58.8
12
23
52.2
9
22
40.9
11
19
57.9
42
81
51.9
2,173
52.4
23,308
53.5
2136
Acute anticoagulant (Male)
15
15
100.0
28
29
96.6
36
40
90.0
40
40
100.0
119
124
96.0
7,994
93.5
78,495
94.2
2137
Acute anticoagulant
(Female)
14
17
82.4
21
23
91.3
19
22
86.4
17
18
94.4
71
80
88.8
3,866
89.5
41,328
91.9
2138
Acute GP IIb-IIIa Inh. (Male)
2
15
13.3
6
29
20.7
5
41
12.2
4
40
10.0
17
125
13.6
2,737
32.1
31,159
37.7
2139
Acute GP IIb-IIIa Inh.
(Female)
1
17
5.9
0
23
0.0
2
22
9.1
0
19
0.0
3
81
3.7
980
22.8
12,373
27.8
2140
Early catheterization (Male)
0
12
0.0
0
24
0.0
0
35
0.0
0
37
0.0
0
108
0.0
5,673
73.3
54,890
73.5
2141
Early catheterization
(Female)
0
12
0.0
0
20
0.0
0
14
0.0
0
15
0.0
0
61
0.0
2,435
70.4
25,730
70.0
2142
Reperfusion (Male)
6
6
100.0
7
7
100.0
18
20
90.0
23
23
100.0
54
56
96.4
3,314
87.7
30,592
85.9
2143
Reperfusion (Female)
3
3
100.0
4
4
100.0
6
6
100.0
7
7
100.0
20
20
100.0
1,177
80.7
11,891
79.9
2144
Time to PCI <= 90 (Male)
4
6
66.7
7
7
100.0
15
15
100.0
19
20
95.0
45
48
93.8
2,090
94.8
18,215
95.0
2145
Time to PCI <= 90 (Female)
1
1
100.0
3
4
75.0
5
5
100.0
5
5
100.0
14
15
93.3
708
93.5
6,860
93.6
2146
In-hospital clinical events
2147
Bleeding events (Male)
0
15
0.0
0
30
0.0
0
41
0.0
0
40
0.0
0
126
0.0
269
3.1
2,313
2.7
2148
Bleeding events (Female)
1
17
5.9
0
23
0.0
0
22
0.0
0
19
0.0
1
81
1.2
185
4.2
1,875
4.1
2149
Discharge therapies
2150
Aspirin (Male)
13
14
92.9
21
21
100.0
26
26
100.0
31
31
100.0
91
92
98.9
6,930
98.8
67,515
98.7
2151
Aspirin (Female)
14
14
100.0
19
19
100.0
15
15
100.0
12
12
100.0
60
60
100.0
3,301
98.4
34,657
97.9
2152
Clopidogrel (Male)
12
14
85.7
14
23
60.9
14
30
46.7
15
31
48.4
55
98
56.1
4,636
62.2
43,884
61.0
2153
Clopidogrel (Female)
13
15
86.7
15
19
79.0
11
18
61.1
9
14
64.3
48
66
72.7
2,312
64.1
23,758
62.9
2154
Beta blocker (Male)
13
13
100.0
23
23
100.0
27
27
100.0
32
32
100.0
95
95
100.0
7,049
97.7
69,766
97.4
2155
Beta blocker (Female)
14
15
93.3
16
16
100.0
17
17
100.0
12
12
100.0
59
60
98.3
3,355
96.3
36,100
96.3
2156
ACE inhibitor or ARB (Male)
1
1
100.0
5
6
83.3
3
4
75.0
1
1
100.0
10
12
83.3
941
90.4
11,412
89.6
2157
ACE inhibitor or ARB
(Female)
2
2
100.0
1
1
100.0
4
5
80.0
7
8
87.5
392
89.7
5,423
88.7
2158
Statin (Male)
13
13
100.0
21
21
100.0
30
30
100.0
32
32
100.0
96
96
100.0
7,178
99.1
69,844
98.8
2159
Statin (Female)
15
15
100.0
18
18
100.0
18
18
100.0
13
13
100.0
64
64
100.0
3,351
98.4
35,250
98.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute and Discharge Therapies by Age
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
2160
Acute therapies (within 24
hours)
2161
ECG <= to 10 min of pres
(<75 years)
14
18
77.8
12
18
66.7
13
16
81.3
16
21
76.2
55
73
75.3
3,057
68.6
32,031
66.9
2162
ECG <= to 10 min of pres
(75+ years)
4
7
57.1
8
19
42.1
4
12
33.3
4
6
66.7
20
44
45.5
1,044
55.7
9,688
54.1
2163
Aspirin at arrival (<75 years)
19
20
95.0
28
28
100.0
40
41
97.6
46
46
100.0
133
135
98.5
8,990
98.1
92,676
98.1
2164
Aspirin at arrival (75+ years)
8
10
80.0
24
25
96.0
20
21
95.2
12
13
92.3
64
69
92.8
3,415
96.6
31,259
96.6
2165
Clopidogrel (<75 years)
16
22
72.7
15
28
53.6
23
40
57.5
28
45
62.2
82
135
60.7
4,856
54.2
50,078
54.1
2166
Clopidogrel (75+ years)
5
10
50.0
15
24
62.5
5
21
23.8
4
13
30.8
29
68
42.7
1,796
52.0
17,219
54.3
2167
Acute anticoagulant (<75
years)
21
22
95.5
26
27
96.3
38
40
95.0
46
46
100.0
131
135
97.0
8,740
94.3
90,529
94.7
2168
Acute anticoagulant (75+
years)
8
10
80.0
23
25
92.0
17
22
77.3
11
12
91.7
59
69
85.5
3,120
86.7
29,294
89.3
2169
Acute GP IIb-IIIa Inh. (<75
years)
3
22
13.6
4
28
14.3
6
41
14.6
4
46
8.7
17
137
12.4
3,058
33.1
36,666
38.7
2170
Acute GP IIb-IIIa Inh. (75+
years)
0
10
0.0
2
24
8.3
1
22
4.6
0
13
0.0
3
69
4.4
659
18.3
6,866
21.1
2171
Early catheterization (<75
years)
0
17
0.0
0
27
0.0
0
38
0.0
0
43
0.0
0
125
0.0
6,422
73.7
65,238
73.6
2172
Early catheterization (75+
years)
0
7
0.0
0
17
0.0
0
11
0.0
0
9
0.0
0
44
0.0
1,686
67.9
15,382
67.5
2173
Reperfusion (<75 years)
7
7
100.0
9
9
100.0
22
22
100.0
28
28
100.0
66
66
100.0
3,703
88.9
35,849
86.6
2174
Reperfusion (75+ years)
2
2
100.0
2
2
100.0
2
4
50.0
2
2
100.0
8
10
80.0
788
73.6
6,634
73.0
2175
Time to PCI <= 90 (<75
years)
5
6
83.3
8
9
88.9
19
19
100.0
22
23
95.7
54
57
94.7
2,327
94.9
21,306
94.8
2176
Time to PCI <= 90 (75+
years)
0
1
0.0
2
2
100.0
1
1
100.0
2
2
100.0
5
6
83.3
471
92.4
3,769
93.3
2177
In-hospital clinical events
2178
Bleeding events (<75 years)
1
22
4.6
0
28
0.0
0
41
0.0
0
46
0.0
1
137
0.7
278
3.0
2,696
2.8
2179
Bleeding events (75+ years)
0
10
0.0
0
25
0.0
0
22
0.0
0
13
0.0
0
70
0.0
176
4.8
1,492
4.4
2180
Discharge therapies
2181
Aspirin (<75 years)
17
18
94.4
22
22
100.0
28
28
100.0
36
36
100.0
103
104
99.0
7,720
98.7
79,456
98.5
2182
Aspirin (75+ years)
10
10
100.0
18
18
100.0
13
13
100.0
7
7
100.0
48
48
100.0
2,511
98.7
22,716
97.9
2183
Clopidogrel (<75 years)
17
19
89.5
14
24
58.3
18
34
52.9
20
37
54.1
69
114
60.5
5,057
61.2
49,602
59.1
2184
Clopidogrel (75+ years)
8
10
80.0
15
18
83.3
7
14
50.0
4
8
50.0
34
50
68.0
1,891
67.6
18,040
70.0
2185
Beta blocker (<75 years)
19
19
100.0
24
24
100.0
32
32
100.0
37
37
100.0
112
112
100.0
7,804
97.4
81,188
97.3
2186
Beta blocker (75+ years)
8
9
88.9
15
15
100.0
12
12
100.0
7
7
100.0
42
43
97.7
2,600
96.7
24,678
96.4
2187
ACE inhibitor or ARB (<75
years)
1
1
100.0
3
3
100.0
5
6
83.3
1
1
100.0
10
11
90.9
971
91.3
12,467
91.0
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute and Discharge Therapies by Age
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
2188
ACE inhibitor or ARB (75+
years)
2189
2190
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
2
2
100.0
3
4
75.0
2
3
66.7
Statin (<75 years)
19
19
100.0
24
24
100.0
34
34
100.0
38
38
Statin (75+ years)
9
9
100.0
15
15
100.0
14
14
100.0
7
7
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
7
9
77.8
362
87.4
4,368
84.7
100.0
115
115
100.0
7,919
98.8
81,266
98.7
100.0
45
45
100.0
2,610
99.0
23,828
98.3
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute and Discharge Therapies by Transfer Status
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
2191
Acute therapies (within 24
hours)
2192
Aspirin at arrival (Transfer
In)
2193
Aspirin at arrival (Nontransfer In)
2194
Clopidogrel (Transfer In)
2195
Clopidogrel (Non-Transfer
In)
2196
Acute anticoagulant
(Transfer In)
2197
Acute anticoagulant (Nontransfer In)
2198
Acute GP IIb-IIIa Inh.
(Transfer In)
2199
Acute GP IIb-IIIa Inh. (Nontransfer In)
2200
Reperfusion (Transfer In)
2201
Reperfusion (Non-transfer
In)
2202
Time to PCI <= 90 (Transfer
In)
2203
Time to PCI <= 90 (Nontransfer In)
2204
Discharge therapies
2205
Aspirin (Transfer In)
2206
Aspirin (Non-transfer In)
2207
Clopidogrel (Transfer In)
2208
Clopidogrel (Non-transfer In)
2209
Beta blocker (Transfer In)
2210
Beta blocker (Non-transfer
In)
2211
ACE inhibitor or ARB
(Transfer In)
2212
ACE inhibitor or ARB (Nontransfer In)
2213
Statin (Transfer In)
2214
Statin (Non-transfer In)
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
5
5
100.0
6
6
100.0
11
11
100.0
3,344
98.2
36,159
98.1
57
96.5
52
53
98.1
186
193
96.4
9,061
97.5
87,776
97.5
27
30
90.0
52
53
98.1
55
5
5
100.0
3
6
50.0
8
11
72.7
1,916
56.8
22,045
60.8
21
32
65.6
30
52
57.7
23
56
41.1
29
52
55.8
103
192
53.7
4,736
52.4
45,252
51.5
5
5
100.0
6
6
100.0
11
11
100.0
3,309
95.7
35,774
95.8
50
57
87.7
51
52
98.1
179
193
92.8
8,551
90.9
84,049
92.3
1
5
20.0
0
6
0.0
1
11
9.1
1,005
29.1
13,320
36.0
58
10.3
4
53
7.6
19
195
9.7
2,712
28.9
30,212
33.4
29
32
90.6
49
52
94.2
3
32
9.4
6
52
11.5
6
3
3
100.0
5
5
100.0
8
8
100.0
1,188
87.0
13,116
84.6
9
9
100.0
11
11
100.0
21
23
91.3
25
25
100.0
66
68
97.1
3,303
85.4
29,367
83.9
1
2
50.0
3
4
75.0
4
6
66.7
189
36.9
2,554
32.3
20
100.0
24
25
96.0
59
63
93.7
2,798
94.5
25,075
94.6
5
7
71.4
10
11
90.9
20
5
5
100.0
5
5
100.0
10
10
100.0
2,837
98.8
31,260
98.8
27
28
96.4
40
40
100.0
36
36
100.0
38
38
100.0
141
142
99.3
7,394
98.6
70,912
98.2
4
5
80.0
4
5
80.0
8
10
80.0
1,990
64.4
21,503
64.6
21
43
48.8
20
40
50.0
95
154
61.7
4,958
62.2
46,139
60.4
5
5
100.0
5
5
100.0
10
10
100.0
2,872
97.6
32,291
97.8
39
39
100.0
39
39
100.0
144
145
99.3
7,532
97.1
73,575
96.7
1
1
100.0
1
1
100.0
341
87.7
5,235
91.0
8
75.0
16
19
84.2
992
91.1
11,600
88.6
25
27
29
28
86.2
96.4
29
39
42
39
69.1
100.0
3
3
100.0
6
7
85.7
6
5
5
100.0
28
28
100.0
39
39
100.0
43
43
100.0
Rev: 5
1
1
100.0
5
5
100.0
10
10
100.0
2,948
98.9
32,244
98.8
40
40
100.0
150
150
100.0
7,581
98.9
72,850
98.5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute and Discharge Therapies by Diabetes Status
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
2215
Acute therapies (within 24
hours)
2216
Aspirin at arrival (Diabetic)
11
12
91.7
21
21
100.0
18
19
94.7
31
31
100.0
81
83
97.6
3,879
97.4
40,368
97.2
2217
Aspirin at arrival (Nondiabetic)
16
18
88.9
30
31
96.8
42
43
97.7
27
28
96.4
115
120
95.8
8,520
97.9
83,472
98.0
2218
Clopidogrel (Diabetic)
8
12
66.7
11
20
55.0
8
18
44.4
17
30
56.7
44
80
55.0
2,033
52.5
21,626
53.2
2219
Clopidogrel (Non-diabetic)
13
20
65.0
18
31
58.1
20
43
46.5
15
28
53.6
66
122
54.1
4,615
54.1
45,615
54.7
2220
Acute anticoagulant
(Diabetic)
10
12
83.3
19
20
95.0
16
19
84.2
31
31
100.0
76
82
92.7
3,665
90.8
38,935
92.6
2221
Acute anticoagulant (Nondiabetic)
19
20
95.0
29
31
93.6
39
43
90.7
26
27
96.3
113
121
93.4
8,189
92.8
80,794
93.7
2222
Acute GP IIb-IIIa Inh.
(Diabetic)
1
12
8.3
2
21
9.5
1
19
5.3
3
31
9.7
7
83
8.4
967
24.1
11,828
28.4
2223
Acute GP IIb-IIIa Inh. (Nondiabetic)
2
20
10.0
3
30
10.0
6
44
13.6
1
28
3.6
12
122
9.8
2,747
31.2
31,669
37.0
2224
Reperfusion (Diabetic)
4
4
100.0
1
1
100.0
7
7
100.0
14
14
100.0
26
26
100.0
1,039
82.2
10,180
80.7
2225
Reperfusion (Non-diabetic)
5
5
100.0
9
9
100.0
17
19
89.5
16
16
100.0
47
49
95.9
3,450
87.0
32,267
85.3
2226
Time to PCI <= 90
(Diabetic)
2
3
66.7
1
1
100.0
6
6
100.0
11
12
91.7
20
22
90.9
619
94.1
5,790
93.1
2227
Time to PCI <= 90 (Nondiabetic)
3
4
75.0
8
9
88.9
14
14
100.0
13
13
100.0
38
40
95.0
2,177
94.6
19,260
95.0
2228
Discharge therapies
2229
Aspirin (Diabetic)
11
11
100.0
14
14
100.0
14
14
100.0
21
21
100.0
60
60
100.0
3,111
98.5
32,382
98.1
2230
Aspirin (Non-diabetic)
16
17
94.1
25
25
100.0
27
27
100.0
22
22
100.0
90
91
98.9
7,115
98.8
69,721
98.5
2231
Clopidogrel (Diabetic)
9
11
81.8
12
15
80.0
9
15
60.0
9
23
39.1
39
64
60.9
2,151
63.0
22,220
62.7
2232
Clopidogrel (Non-diabetic)
16
18
88.9
16
26
61.5
16
33
48.5
15
22
68.2
63
99
63.6
4,793
62.7
45,379
61.2
2233
Beta blocker (Diabetic)
11
11
100.0
13
13
100.0
14
14
100.0
23
23
100.0
61
61
100.0
3,279
97.7
34,782
97.3
2234
Beta blocker (Non-diabetic)
16
17
94.1
25
25
100.0
30
30
100.0
21
21
100.0
92
93
98.9
7,121
97.1
71,014
96.9
2235
ACE inhibitor or ARB
(Diabetic)
2
2
100.0
3
4
75.0
2
3
66.7
1
1
100.0
8
10
80.0
494
91.0
6,296
88.7
2236
ACE inhibitor or ARB (Nondiabetic)
1
1
100.0
3
3
100.0
5
6
83.3
9
10
90.0
838
89.7
10,529
89.7
2237
Statin (Diabetic)
11
11
100.0
13
13
100.0
16
16
100.0
24
24
100.0
64
64
100.0
3,263
98.9
34,001
98.7
2238
Statin (Non-diabetic)
17
17
100.0
25
25
100.0
32
32
100.0
21
21
100.0
95
95
100.0
7,261
98.8
71,024
98.5
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute and Discharge Therapies by Creatinine Clearance
Sample Hospital
2011Q3
2011Q4
2012Q1
US
Comparison
Group Pts
R4Q
2012Q2
My Hospital R4Q
Line#
2239
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
US Registry Pts
R4Q
%
Num
%
Acute therapies (within 24
hours)
2240
Aspirin at arrival (<50
cc/min)
10
12
83.3
24
24
100.0
20
21
95.2
17
18
94.4
71
75
94.7
2,924
96.1
27,493
95.8
2241
Aspirin at arrival (50+
cc/min)
17
18
94.4
28
29
96.6
40
41
97.6
41
41
100.0
126
129
97.7
9,354
98.3
95,319
98.3
2242
Clopidogrel (<50 cc/min)
6
12
50.0
13
23
56.5
8
21
38.1
8
18
44.4
35
74
47.3
1,423
47.7
14,475
51.5
2243
Clopidogrel (50+ cc/min)
15
20
75.0
17
29
58.6
20
40
50.0
24
40
60.0
76
129
58.9
5,151
55.4
52,209
55.0
2244
Acute anticoagulant (<50
cc/min)
10
12
83.3
21
24
87.5
18
22
81.8
16
17
94.1
65
75
86.7
2,644
85.2
25,633
88.2
2245
Acute anticoagulant (50+
cc/min)
19
20
95.0
28
28
100.0
37
40
92.5
41
41
100.0
125
129
96.9
9,107
94.6
93,168
95.0
2246
Acute GP IIb-IIIa Inh. (<50
cc/min)
0
12
0.0
2
23
8.7
0
22
0.0
0
18
0.0
2
75
2.7
507
16.4
5,417
18.9
2247
Acute GP IIb-IIIa Inh. (50+
cc/min)
3
20
15.0
4
29
13.8
7
41
17.1
4
41
9.8
18
131
13.7
3,164
33.0
37,697
38.7
2248
Early catheterization (<50
cc/min)
0
7
0.0
0
20
0.0
0
9
0.0
0
11
0.0
0
47
0.0
1,277
63.5
12,296
63.7
2249
Early catheterization (50+
cc/min)
0
17
0.0
0
24
0.0
0
40
0.0
0
41
0.0
0
122
0.0
6,735
74.2
67,683
74.3
2250
Reperfusion (<50 cc/min)
2
2
100.0
2
2
100.0
3
4
75.0
2
2
100.0
9
10
90.0
608
71.5
5,461
70.4
2251
Reperfusion (50+ cc/min)
7
7
100.0
9
9
100.0
21
22
95.5
28
28
100.0
65
66
98.5
3,811
88.8
36,488
86.8
2252
Time to PCI <= 90 (<50
cc/min)
1
1
100.0
2
2
100.0
2
2
100.0
2
2
100.0
7
7
100.0
367
92.4
3,055
93.0
2253
Time to PCI <= 90 (50+
cc/min)
4
6
66.7
8
9
88.9
18
18
100.0
22
23
95.7
52
56
92.9
2,381
94.7
21,776
94.8
2254
In-hospital clinical events
2255
Bleeding events (<50
cc/min)
0
12
0.0
0
24
0.0
0
22
0.0
0
18
0.0
0
76
0.0
169
5.3
1,521
5.1
2256
Bleeding events (50+
cc/min)
1
20
5.0
0
29
0.0
0
41
0.0
0
41
0.0
1
131
0.8
283
2.9
2,628
2.7
2257
Discharge therapies
2258
Aspirin (<50 cc/min)
11
11
100.0
16
16
100.0
14
14
100.0
10
10
100.0
51
51
100.0
2,083
97.9
19,817
97.7
2259
Aspirin (50+ cc/min)
16
17
94.1
24
24
100.0
27
27
100.0
33
33
100.0
100
101
99.0
8,057
98.9
81,566
98.6
2260
Clopidogrel (<50 cc/min)
9
11
81.8
14
17
82.4
12
16
75.0
6
12
50.0
41
56
73.2
1,504
64.4
14,901
67.1
2261
Clopidogrel (50+ cc/min)
16
18
88.9
15
25
60.0
13
32
40.6
18
33
54.6
62
108
57.4
5,376
62.3
52,193
60.3
2262
Beta blocker (<50 cc/min)
9
10
90.0
15
15
100.0
13
13
100.0
11
11
100.0
48
49
98.0
2,195
96.8
21,364
96.4
2263
Beta blocker (50+ cc/min)
18
18
100.0
24
24
100.0
31
31
100.0
33
33
100.0
106
106
100.0
8,119
97.4
83,681
97.2
2264
ACE inhibitor or ARB (<50
cc/min)
2
2
100.0
2
3
66.7
3
4
75.0
7
9
77.8
313
86.0
3,806
82.2
2265
ACE inhibitor or ARB (50+
1
1
100.0
4
4
100.0
4
5
80.0
11
90.9
1,006
91.6
12,911
91.7
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
1
1
100.0
10
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Overall AMI Subgroups
Acute and Discharge Therapies by Creatinine Clearance
Sample Hospital
2011Q3
2011Q4
2012Q1
2012Q2
My Hospital R4Q
Line#
Description
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
Num
Den
%
US
Comparison
Group Pts
R4Q
Num
US Registry Pts
R4Q
%
Num
%
cc/min)
2266
Statin (<50 cc/min)
10
10
100.0
15
15
100.0
16
16
100.0
11
11
100.0
52
52
100.0
2,153
98.9
20,282
98.2
2267
Statin (50+ cc/min)
18
18
100.0
24
24
100.0
32
32
100.0
34
34
100.0
108
108
100.0
8,280
98.9
84,004
98.7
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013
Detail Section Foot Notes
1
2
3
4
5
6
7
8
9
IMPORTANT INTERPRETATION NOTE: Median times by quarter are plotted in the graph, thus downward slope indicates improvement as shorter times are preferable
Among non-transfer-in pts
Among non-transfer-in pts who received an ECG
Pre-procedure is anytime from hospital presentation up to 1-hour pre-procedure
Peri-procedure is 1-hour pre-procedure to anytime post-procedure
Excludes transfers out
Excludes transfers out, Any PCI, including Primary PCI
Early Cath defined as within 48 hours
RAM and Bleeding - See the Report Companion Guide for specifics
©2011 American College of Cardiology Foundation
®
®
NCDR ACTION Registry - GWTG™
Rev: 5
Aggregation Date: Aug 31, 2012 11:59:59 PM
Publish Date: Jan 17, 2013